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Abstract 
The Role of Adipose Tissue in Canine Cranial Cruciate Ligament Disease 
Wipawee Saengsoi 
Cranial cruciate ligament disease (CCLD) is one of the most important causes 
of pelvic limb lameness in dogs, and its prevalence is increased in dogs that are 
overweight. To date, the mechanisms underlying the association between obesity 
and CCLD in dogs have not been clarified. Therefore, the general aims of this thesis 
were to examine the role of both the mechanical and humoral effects of adipose 
tissue on the clinical presentation and pathogenesis of dogs with CCLD. Dogs 
suffering from CCLD were clinically evaluated by calculating lameness scores, force 
plate analysis, radiographic examination, and dual-energy X-ray absorptiometry 
(DEXA). Increased bodyweight was associated with severity of lameness, as 
determined by force plate analysis, but there was no association with body fat mass 
determined by DEXA. In vitro studies were also used to examine interactions between 
adipose tissue and the canine cruciate ligament. In co-culture experiments, adipose 
tissue had a catabolic effect on glycosaminoglycan content in CCL explants. 
Furthermore, various associations between key adipokines (adiponectin, leptin, 
visfatin) with disease biomarkers in CCL tissues and joint fluid were discovered. For 
example, an association was identified between synovial fluid TNF-α concentration 
and the gene expression of adiponectin and visfatin in infrapatellar fat pad (IPFP) 
adiponectin and subcutaneous (SC) fat, respectively. Associations were also seen 
between IPFP leptin gene expression and MMP-13 gene expression, and between 
both IPFP and SC visfatin gene expression and CCL TNF-α gene expression. Finally, 
synovial fluid leptin concentration was positively associated with the degree of 
lameness. In conclusion, the studies undertaken in this thesis have demonstrated 
that adipose tissue may have both mechanical and humoral effects on the cruciate 
ligament in dogs. These findings provide a basis for further studies into the 
pathogenesis of CCLD, as well as revealing possible targets for therapeutic 
intervention. 
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Chapter 1 Introduction 
1.1 Obesity in man and companion animals 
Adiposity is fat stored in the fatty tissue of the body. Obesity is defined as a 
disease where excess body fat has accumulated and frequently results in various 
adverse effects on health and longevity (National Institutes of Health, 1985). 
Increased body fat accumulation is associated with an increase in adipocyte size and, 
in extreme obesity, adipocyte numbers are also increased (Hirsch and Batchelor, 
1976). Usually, it requires a prolonged period of imbalance between energy intake 
and expenditure, with intake calories exceeding calories burned, in order for obesity 
to develop (National Institutes of Health, 1985).  
1.1.1 Assessment of obesity 
There are different methods that can be used to assess body condition in man, 
for example body mass index (BMI), anthropometrics, skinfold thickness, 
bioimpedance, dilution technique, hydrostatic weighing, air displacement 
plethysmography, dual-energy X-ray absorptiometry and computerised tomography 
scans (Beechy et al., 2012). Most epidemiological studies and clinical practices 
commonly use BMI given its strong correlation with fat mass densitometry and due 
to the fact that neither specialist nor extra equipment is required (Kopelman, 2000). 
BMI can be calculated by dividing body weight (kg) by height (m2) (VanItallie et al., 
1990). Using the classification from the WHO, human beings can be classified as 
underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), 
obese class I (30.0-34.9 kg/m2), obese class II (35.0-39.9 kg/m2) and obese class III 
(≥40.0 kg/m2). This is generally used for adults of 20 years and older (WHO, 2000). 
However, the associations of BMI and comorbidities are not always stable in different 
populations (Swinburn et al., 1996). BMI does not distinguish between the type of fat 
such as subcutaneous (SC) and visceral fat. Therefore, other assessment methods 
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such as waist circumference and waist-to-hip ratio should be used to measure intra-
abdominal (visceral) fat, which has been shown to be more connected to obesity-
related illness (Han et al., 1995). 
Bodyweight measurement is routinely used in veterinary practice, and it can 
be the first indicator for observing weight loss or gain in companion animals (German, 
2006). Companion animals are classified as overweight when their bodyweight is 
more than 10% above their ideal weight and classified as obese when their 
bodyweight exceeds 20% of their optimums (German, 2006). However, although 
bodyweight provides an objective measurement of body mass, it cannot indicate 
adiposity or body composition (Toda et al., 1998). Several methods have been 
developed to assess obesity in dogs and cats (Table 1.1). Body condition scoring (BCS) 
is often used by veterinarians because it is practical, inexpensive and non-invasive to 
the animal providing a semi-quantitative method of evaluating body composition 
(Burkholder, 2000). BCS uses visual assessment and palpation on specific body 
regions including rib cage, waist, lumbar region, and base of the tail. Although various 
systems exist (Scarlett and Donoghue, 1998, German et al., 2006, Witzel et al., 2014), 
it is now recommended that the 9-point BCS system (Laflamme, 1997a, Laflamme, 
1997b) be used exclusively to aid consistency (Freeman et al., 2011). It has been 
validated for repeatability, reproducibility by trained investigators and owners, as 
well as correlating well with body fat composition in dogs and cats (German et al., 
2006). In this scoring system, a score of 4 or 5 represents an ideal body condition, a 
score of 1 represents an emaciated animal and a score of 9 represents a grossly obese 
animal (Laflamme, 1997a, Laflamme, 1997b). BCS also can determine the 
approximate degree of excess bodyweight in obese dogs with each score correlating 
with approximately 10% to 15% of excess bodyweight (German et al., 2009). 
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Table 1.1 Methods for body composition analysis in dogs and cats. 
(adapted from German et al., 2006) 
Common research techniques 
Chemical analysis 
Densitometry 
Total body water 
Total body potassium 
Absorptiometry 
   Photon absorptiometry 
      Single-photon absorptiometry  
      Dual-photon absorptiometry  
   X-ray absorptiometry 
      Single-energy X-ray absorptiometry  
      Dual-energy X-ray absorptiometry  
Ultrasound 
Electrical impedance 
Common clinical methods 
Bodyweight 
Morphometric methods  
   Body condition score 
      9-Point scale 
      5-Point scale 
 
Other methods 
Muscle metabolite markers 
Neutron activation analysis 
Electrical conductance 
Near infrared interactance  
Computed tomography 
Magnetic resonance imaging 
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Dual-energy X-ray absorptiometry (DEXA) is a non-invasive technique that can 
be used to quantify bone density and body composition (including lean tissue mass, 
fat mass, and bone mineral content) in humans (Lang et al., 2015, Rae et al., 2016) 
and animals (Lang et al., 2015, Rae et al., 2016). The method by which DEXA estimates 
body composition is based on the principle that the intensity of X-ray beams is 
attenuated in proportion to tissue mass they pass through. The X-ray beam, which is 
composed of two different frequencies, is impeded by bone, fat and lean tissue (Grier 
et al., 1996). Bone mineral content, lean body mass, and fat are then calculated with 
commercially available software and compared with standard values in an object of 
known density (Grier et al., 1996). The advantages of DEXA include a short scan time, 
precise measurement with its high-resolution images, the ability to analyse different 
body regions, low radiation dose and being relatively inexpensive (Blake and 
Fogelman, 2007). DEXA is sensitive enough to measure relatively small changes in 
bone mass, so it has been used for screening and diagnosis of metabolic conditions 
associated with bone loss such as osteoporosis, measuring fracture healing, growth 
studies and sports medicine in man (Maffulli et al., 1997, Kesman et al., 2010, Lerch 
et al., 2013). In addition, measurement of total body composition by DEXA is useful 
in nutritional-related studies for determining energy expenditure and stores, protein 
mass, and for defining relative hydration (Grier et al., 1996). In animals, DEXA is used 
in the study of overweight animals as well as in neonatal and pharmacological studies 
(Grier et al., 1996, German et al., 2009). Furthermore, recent studies have effectively 
used DEXA to monitor canine body composition during weight loss (Larsson et al., 
2014, German et al., 2015). 
1.1.2 Epidemiology of obesity 
In 2013, one third of the world’s adult population were overweight or obese 
(Ng et al., 2014). With time there is an increasing risk of death due to obesity due to 
fatal co-morbidities such as coronary heart disease, hypertension, stroke, certain 
types of cancer and type 2 diabetes mellitus (Haslam and James, 2005). In England, 
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62% of adults and 28% of children aged between 2 and 15 are overweight or obese 
(GOV.UK, 2015). Being overweight and obese also has financial implications for the 
wider economy: the costs for the National Health Service (England) to treat 
overweight, obesity and related co-morbidities ranged between £479.3 million in 
1998 (National Audit Office, 2001) and £4.2 billion in 2007 (Butland et al., 2007). In 
the United States, obesity related costs are predicted to reach as much as $956 billion 
by 2030 (Wang et al., 2008). Once considered only to be a problem of high income 
countries, obesity is now also on the rise in low- and middle-income countries across 
many demographic groups, especially in urban areas (Mitchell and Shaw, 2015, Atay 
and Bereket, 2016). 
As in men, the incidence of obesity in companion animals is also increasing. 
Obesity is the most common medical disorder that affects health of dogs and cats, 
especially in developed countries (Clark and Hoenig, 2016), with recent reports 
estimating that 34% to 59% of dogs (McGreevy et al., 2005, Courcier et al., 2010b) 
and 26% to 63% of cats (Colliard et al., 2009, Courcier et al., 2010a, Cave et al., 2012) 
are overweight or obese.   
1.1.3 Causes of obesity  
Factors influencing the development of overweight and obesity in humans 
include diet, physical activity patterns, environment, society and individual 
susceptibility (WHO, 2000). Like in humans, the causes of obesity in pets are 
multifactorial. Age, genetics (or breed), social and environmental conditions (dietary 
exposure and physical activity) play a major role in the development of the disease 
(Edney and Smith, 1986, Heber, 2010, Vanden Bosch et al., 2014). In addition, risk 
factors for dog and cat obesity also include sex, gonadal status and neutering (Root 
et al., 1996, Fettman et al., 1997), hormonal influences such as hypothyroidism; 
(Jeusette et al., 2006), some infectious diseases such as canine distemper virus; 
(Verlaeten et al., 2001), rapid early life weight gain, behavioural factors and owner 
factors (German, 2016a). However, a positive mismatch between energy intake and 
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expenditure is the key factor of development of obesity and overfeeding in dogs and 
cats appear to be the main cause of the disease (German, 2006).  
1.1.4 The clinical importance of obesity 
Obesity is associated with various morbidities (Table 1.2) and increases mortality risk 
in both humans and animals (German et al., 2010b, Linder and Mueller, 2014). In 
man, obesity is known to increase the incidence of serious diseases such as 
cardiovascular disease, stroke and type 2 diabetes mellitus (Dankner et al., 2009, 
Friedemann et al., 2012). Obesity can also lead to neurological, pulmonary, 
gastrointestinal, renal and musculoskeletal disorders as well as various forms of 
psychopathy and a reduced quality of life (Ebbeling et al., 2002). In companion 
animals, obesity increases the risk of developing several health abnormalities. These 
include: cardiorespiratory disease, endocrine disorders, metabolic diseases, diabetes 
mellitus, hepatic lipidosis, urinary tract disease, dermatopathies, cancer and 
orthopaedic diseases (DeFronzo and Ferrannini, 1991, Scarlett and Donoghue, 1998, 
Clark and Hoenig, 2016).
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Table 1.2 Diseases associated with obesity in man and companion animals. 
)adapted from German et al ., 2010, Linder and Mueller, 2014( 
Body System Species 
Human Dog Cat 
Endocrine and lipid 
metabolism 
Type 2 diabetes 
mellitus  
Metabolic syndrome 
Dyslipidaemias 
Hypothyroidism 
Hyperadrenocorticism 
Diabetes mellitus 
Insulin resistance 
Hyperinsulinaemia 
Metabolic syndrome 
Impaired  
glucose tolerance 
Diabetes mellitus 
Hepatic lipidosis 
Dyslipidaemia 
Hypercholesterolemia 
Hypertriglyceridemia 
Cardiorespiratory Coronary heart 
disease 
Atherosclerosis 
Hypertension 
Obstructive  
Sleep apnoea 
Asthma 
Cardiac alterations 
Tracheal collapse 
Airway dysfunction 
Hypertension 
Portal vein thrombosis 
Myocardial hypoxia 
Heatstroke 
Cardiac alterations 
Orthopaedic and 
impaired mobility 
Osteoarthritis 
Musculoskeletal pain 
Gout 
Osteoarthritis 
Cruciate ligament disease 
Humeral condylar fractures 
Intervertebral disc disease 
Hip dysplasia 
Increased lameness 
Neoplasia Breast  
Renal  
Endometrial 
Prostatic 
Oesophageal 
Colorectal 
Hepatocellular 
Transitional cell carcinoma 
Mammary carcinoma 
Increased neoplasia risk 
Urogenital (Diabetic) 
nephropathy 
Urinary tract disease 
Calcium oxalate urolithiasis 
Transitional cell carcinoma 
Glomerular disease 
Dystocia 
Increased risk of  
urinary tract disease 
Urolithiasis 
 
Alimentary Pancreatitis  
Hepatic steatosis 
Cirrhosis 
Pancreatitis 
Oral disease 
 
Increased  
oral and gastrointestinal 
disease 
 
19 
 
1.1.5 Treatment and management of obesity 
The key treatments of obesity in people include lifestyle management, 
pharmacological and surgical therapies or a combination of these methods (Quante 
et al., 2015). The treatment chosen depends on disease severity, the presence of 
weight-related complications and risks for each patient. A decreased caloric intake 
and increased physical activity are key lifestyle and behavioural interventions, which 
are considered first-line therapy for those overweight and obese (Cefalu et al., 2015). 
The variety of dietary options, social networks and structured weight loss 
programmes are increasing, helping to reduce morbidity and improve the life quality 
of obese people. Several drugs have been developed and approved to use for long-
term weight management in humans such as the lipase inhibitor, the serotonin 2c 
receptor agonist and the glucagon-like peptide-1 receptor agonist (Apovian et al., 
2015). However, medical or non-surgical treatment may not produce effective long-
term maintenance of weight loss for the morbidly obese and therefore surgical 
management (bariatric surgery) may be the most feasible treatment in these cases 
(Quante et al., 2015). There are many techniques for bariatric surgeries including 
jejunoileal bypass, biliopancreatic diversion, gastroplasty and Roux-en-Y gastric 
bypass (Fobi, 2004). Nevertheless, these surgeries are complicated and patients 
undergoing these procedures need lifelong nutritional supplements and frequent 
medical monitoring (Fobi, 2004). 
Weight management principles in companion animals are similar to these in 
humans. Dietary energy restriction using purpose-formulated foods are most widely 
used with the aim of delivering essential nutrients while reducing calorie intake 
(Hoenig and Rand, 2006). Moreover, there are several methods for reducing calorie 
density in animal foods such as reducing fat, adding moisture, or adding fiber 
(Laflamme, 2005). Previous study has suggested that approximately 1% of body 
weight loss per week prevents the risk of nutrient deficiency, loss of lean body mass 
and rebound weight gain (Laflamme and Hannah, 2005). Increasing physical activities 
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such as walking, swimming or using interactive toys are also beneficial for pets to 
maintain their weight loss (Wakshlag et al., 2012). 
In addition to dedicated weight loss diets, feeding management and exercise, 
owner education is critically important for long-term successful weight control in 
companion animals (Bland et al., 2009). However, many owners do not recognise that 
their companion animals are overweight or obese. Therefore, veterinarians have an 
important role to evaluate the BCS of pets and discuss with clients the importance of 
maintaining an ideal BCS (Linder and Mueller, 2014). Weight loss drugs such as 
dirlotapide and mitratapide have been used in pets (Klonoff, 2007, Dobenecker et al., 
2009). However, these two licensed drugs are no longer available due to unpopular 
usage in clinical practice (German, 2016b). 
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1.2 Adipose tissue and adipokines 
Adipose tissue is mainly located in the SC layer and deposited around visceral 
organs (Cinti, 2005). The general roles of adipose tissue are to store energy in the 
form of lipids, provide protective cushions of internal organs and insulate the body 
(Rosen and Spiegelman, 2014). The amount of adipose tissue in the body is another 
indicator for obesity in animals and humans (National Institutes of Health, 1985, 
Zoran, 2010). In mammals include human, adipose tissue can be divided into two 
major types: white adipose tissue (WAT) and brown adipose tissue (BAT). WAT 
represents the bulk of the adipose tissue in the body (Fantuzzi, 2005). It is the site of 
energy storage with triacylglycerols stored in adipocytes and provides insulation 
(Shapiro and Zinder, 1972). In contrast, BAT contains an abundance of mitochondria 
for its heat-generating properties and it is present in higher quantities in the new-
born mammal such as human than in the adult (Nedergaard and Cannon, 2017). In 
addition, brown in white (brite or beige) adipose depots, which look white in the 
adult but are functionally close to that of BAT in the new-born, have also been 
distinguished in humans and small mammals (Walden et al., 2012).  
Adipose or fatty tissue is loose connective tissue primarily composed of 
adipocytes (adipose cells or fat cells) (Cinti, 2005). Adipose tissue has a stromal 
vascular fraction that contains preadipocytes, connective tissue matrix, nerve tissue, 
vascular endothelial cells and immune cells (Frayn et al., 2003, Fain et al., 2004, Klein-
Wieringa et al., 2011). In recent years, adipose tissue has been recognised as an active 
endocrine organ in many species (Kershaw and Flier, 2004). Adipocytes synthesise 
and release an array of chemical mediators, named adipokines, examples of which 
include adiponectin, leptin and visfatin (Lagowska and Jeszka, 2011). Adipokines act 
upon autocrine, paracrine and endocrine signals which have potent effects on 
systemic metabolic homeostasis (Kershaw and Flier, 2004). Moreover, many 
biological proteins including acute phase proteins, chemokines (e.g. macrophage 
chemotactic protein-1; MCP-1) and cytokines (e.g. tumour necrosis factor-alpha; 
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TNF-α, interleukin-6; IL-6) have been found to be secreted from non-adipocyte 
fraction of adipose tissue (Fain et al., 2004). Activation of adipose tissue macrophages 
within adipose depots can lead to the development of an obesity-induced pro-
inflammatory state (Odegaard and Chawla, 2008), which may predispose to various 
diseases such as obesity-induced insulin resistance, type 2 diabetes mellitus, 
inflammatory bowel disease, osteoarthritis (OA) and rheumatoid arthritis (Fantuzzi, 
2005, Klein-Wieringa et al., 2011, Clark and Hoenig, 2016). Therefore, adipose tissue 
and adipokines are involved in a complex network coordinating a variety of biological 
processes in the body.  
1.2.1 Leptin 
Leptin, a 16-kDa polypeptide containing 167 amino acids, was the first 
adipokine to be discovered in 1994 and was called obese protein at that time (Zhang 
et al., 1994). The discovery of this adipokine demonstrated that adipose tissue was 
not simply an organ for energy storage but, instead, was an active endocrine organ 
(Kershaw and Flier, 2004). Leptin is primarily produced from adipocytes and it is 
secreted into blood circulation in direct proportion to adipocyte volume (Lönnqvist 
et al., 1997). Leptin can play a role in metabolic signalling throughout the body system 
(Myers et al., 2008). It often increases with increasing adiposity and is significantly 
correlated with total body fat mass, both in humans and companion animals (Monti 
et al., 2006, Ishioka et al., 2007, Ruhl et al., 2007, Martin-Gimenez et al., 2016). The 
circulating leptin concentration displays a diurnal rhythm and is at its highest 
concentrations at night, but its concentration can also be affected by meal times 
(Saladin et al., 1995). In addition, increased leptin expression and secretion are 
regulated by several factors such as insulin, glucocorticoids, TNF-α and oestrogens 
(Margetic et al., 2002). Conversely, its function is reduced by β3-adrenergic activity, 
somatostatin, growth hormone and free fatty acids (Margetic et al., 2002). Leptin 
plays critical roles in regulating appetite, energy expenditure and body weight 
homeostasis via hypothalamic pathways (Zhang et al., 1994, Elmquist, 2001). Leptin 
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stimulates fatty acid oxidation and glucose uptake (Minokoshi et al., 2002). It also has 
effects on the immune system by influencing T lymphocyte function, monocyte 
activation, phagocytosis, and cytokine production (Lord et al., 1998, Farooqi et al., 
2002). An increased concentration of circulating leptin was found to be associated 
with negative outcomes in cardiovascular disease in humans (Schulze and Kratzsch, 
2005) and in dogs (Fonfara et al., 2011). Leptin is also expressed in other tissues 
including the gastrointestinal system, skeletal muscle and the female reproductive 
system (Hoggard et al., 1997, Wang et al., 1998, Liu et al., 2003). 
1.2.2 Adiponectin 
Adiponectin was discovered in 1995 and has been described by different 
names including Acrp30 (adipocyte complement-related protein of 30 kDa), apM1 
(adipose most abundant gene transcript 1), GBP28 (gelatin binding protein of 28 kDa) 
and adipoQ (Scherer et al., 1995, Hu et al., 1996, Maeda et al., 1996, Nakano et al., 
1996). Adiponectin is a 30-kDa polypeptide hormone containing an N-terminal signal 
sequence, a variable region, a collagen-like domain and a C-terminal globular domain 
(Scherer et al., 1995). Adiponectin is mainly secreted from adipose tissue during 
adipocyte differentiation (Meier and Gressner, 2004). Its secretion is stimulated by 
insulin and PPARγ receptor agonists, whereas TNF-α (tumor necrosis factor-α) and 
PPARα receptor agonists suppress it (Rajala and Scherer, 2003). The main functions 
of adiponectin include enhancing insulin sensitivity, increasing fatty acid oxidation 
and reducing gluconeogenesis in liver and skeletal muscle (Kershaw and Flier, 2004, 
Galic et al., 2010). In addition, adiponectin has protective properties with regards to 
atherosclerosis by reducing the inflammatory reaction in atherogenesis (Pischon et 
al., 2004). Many studies have demonstrated that plasma adiponectin is negatively 
associated with body fat mass, BMI, fasting insulin and plasma triglyceride 
concentrations (Cnop et al., 2003, Goropashnaya et al., 2009). Decreased serum 
adiponectin concentration is related to an increased risk of cardiovascular disease 
and type 2 diabetes mellitus, whilst a high serum adiponectin concentration has been 
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reported in cases of renal failure, type 1 diabetes, and anorexia (Weyer et al., 2001, 
Schondorf et al., 2005, Lagowska and Jeszka, 2011). In dogs and cats, adiponectin is 
also produced by mature adipocytes and highly expressed in WAT (Zoran, 2010). The 
nucleotide and amino acid sequences of companion animal adiponectin show strong 
similarity to those of other species especially between dogs and human (Brunson et 
al., 2007). In dogs, plasma adiponectin concentration negatively correlates with fat 
mass, and the circulating concentration of adiponectin is markedly lower in obese 
than in normal-weight dogs (Brunson et al., 2007, Piantedosi et al., 2016). Moreover, 
increased body fat mass is negatively correlated with low- and high-molecular weight 
of plasma adiponectin ratio in cats (Bjornvad et al., 2014). These studies suggest 
similar roles between adiponectin and leptin in the development of metabolic 
conditions such as insulin resistance, and type 2 diabetes in companion animals 
(Zoran, 2010). However, there are still relatively few studies on the roles of 
adiponectin in the development of diseases in dogs and cats. 
1.2.3 Visfatin 
Visfatin was initially discovered in 1994 as a growth factor for the maturation 
of B lymphocyte precursors, so it was named pre-B-cell colony-enhancing factor 
(PBEF) (Samal et al., 1994). Later, it was termed nicotinamide 
phosphoribosyltransferase (Nampt) due to its enzymatic role in nicotinamide 
adenine dinucleotide (NAD) biosynthesis (Rongvaux et al., 2002). Visfatin is 52-kDa 
adipokine synthesised by many tissues including leucocytes of peripheral blood 
(Samal et al., 1994), adipose tissue macrophages (Curat et al., 2006), hepatocytes 
(Garten et al., 2010), skeletal muscles (Costford et al., 2010), chondrocytes (Gosset 
et al., 2008) and synovium (Laiguillon et al., 2014). The connection of serum visfatin 
concentration and obesity status is controversial as well as its expression in different 
adipose tissue depots (Zahorska-Markiewicz et al., 2007, Derosa et al., 2013, 
Sitticharoon et al., 2014, Nourbakhsh et al., 2015). Nevertheless, there are known to 
be significant links between visfatin and inflammation, endothelial dysfunction and 
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atherosclerosis (Hognogi and Simiti, 2016). One in-vitro study has shown that 
recombinant visfatin enhances the production of pro-inflammatory cytokines, IL-1β, 
TNF-α, and IL-6 in human monocytes (Moschen et al., 2007). Some studies have also 
found an increased concentration of plasma visfatin in patients with type 1 diabetes 
mellitus (Haider et al., 2006), type 2 diabetes mellitus (Chen et al., 2006a), coronary 
artery disease (Hognogi and Simiti, 2016), rheumatoid arthritis (Otero et al., 2006) 
and OA (Laiguillon et al., 2014). Moreover, in dogs with acute pancreatitis or diabetes 
mellitus, serum visfatin concentrations were to be found significantly higher than in 
healthy dogs (Paek et al., 2014, Kim et al., 2015). Therefore, visfatin may be more 
related to obesity-induced inflammation than to fat accumulation and can be 
considered as a pro-inflammatory adipokine (Friebe et al., 2011). 
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1.3 The stifle (knee) joint in the dog 
The stifle is located in the pelvic limbs of quadruped mammals, including dogs, 
and is equivalent to the human knee joint (Gupte et al., 2007). The dog is a digitigrade 
that walks on four digits thus some joint function and movement varies from 
ungulates and humans (Gupte et al., 2007). The stifle joint is the largest synovial joint 
and one of the most complex biomechanical systems in the body (Carpenter and 
Cooper, 2000). The anatomical structure of the stifle joint is composed of different 
parts: bones, cartilage, ligaments, synovial fluid and infrapatellar fat pad. 
1.3.1 Bones and cartilage 
The stifle joint contains the articulations of three bones: the distal femur, the 
proximal tibia and the patella (Robbins, 1990). The ends of these bones are covered 
with articular cartilage that help the bones move smoothly across each other during 
flexion and extension (Arnoczky, 1993). Two C-shaped fibrocartilaginous discs that sit 
between the femoral condyles and the tibial plateau are the medial and the lateral 
menisci (Arnoczky and Warren, 1983) (Figure 1.1). In man, the menisci primarily 
perform a load-transmitting function of more than 50% of the compressive load to 
which the knee joint is subjected during weight bearing (Bessette, 1992). Therefore, 
they act as shock absorbers and assist with lubrication between the femur and the 
tibia (Clark et al., 1999). They also improve joint stability by deepening the articular 
surface of the tibial plateau in dogs (Robbins, 1990, Arnoczky, 1993).  
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Figure 1.1 Cranial view of a canine stifle joint. 
The figure shows cranial view of a canine stifle joint, which is composed of intercondylar 
notch, cranial and caudal cruciate ligament, medial and lateral meniscus and long digital 
extensor tendon (Adapted from Allaith, 2016, with permission (Thesis, University of 
Liverpool)). 
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1.3.2 Ligaments of the stifle 
Ligaments are tough bands of fibrous tissue that attach one bone to another 
and stabilise joints. They are composed of longitudinal collagen fibres and spindle-
shaped cells called fibrocytes or ligamentocytes (Amiel et al., 1984, Vasseur et al., 
1985). Collagen, glycosaminoglycans (sGAG) and elastin are the key components in 
the extracellular matrix of the canine cruciate ligament (Comerford et al., 2005, Smith 
et al., 2014, Kharaz et al., 2016). Type I collagen is the predominant collagen found in 
ligaments (> 85%) and is consequently related to mechanical strength of ligaments 
(Liu et al., 1995). The large aggregating proteoglycans such as decorin and biglycan 
also play a role in viscoelasticity and act as a lubricant between collagen fibres in 
ligaments (Amiel et al., 1995). 
There are four ligaments that primarily stabilise the canine stifle joint: cranial 
cruciate and caudal cruciate ligaments and medial and lateral collaterals (Arnoczky 
and Marshall, 1977). The cruciate ligaments are located inside the stifle joint (Figure 
1.1). They cross each other with the cranial cruciate ligament (CCL) (anterior cruciate 
ligament; ACL, in humans) at the front of the joint and the caudal cruciate ligament 
(posterior cruciate ligament in humans) at the back (Arnoczky and Marshall, 1977). 
The CCL arises from a fossa on the caudomedial aspect of the lateral femoral condyle, 
and some of the fibres come from the caudolateral aspect of the intercondylar area. 
It then tightens, spirals passing cranially, medially, and distally to insert in a fan-like 
fashion primarily on the cranial intercondyloid area of the tibia (Heffron and 
Campbell, 1978, Stouffer et al., 1983). The canine CCL can also be divided into two 
distinct bundles distinguished from individual attachment sites, the craniomedial 
band and the larger caudolateral band which spirals laterally between attachments 
(Arnoczky and Marshall, 1977). The orientation of the CCL prevents the tibia from 
shifting forward relative to the femur (Arnoczky and Marshall, 1977). The caudal 
cruciate ligament originates from the intercondylar notch on the lateral side of the 
medial femoral condyle. The ligament runs caudodistally crossing medial to the CCL 
and inserting on the medial aspect of the popliteal notch of the tibia. The caudal 
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cruciate ligament functions to prevent caudal displacement of the tibia in relation to 
the femur. Moreover, both cruciate ligaments also control the stifle joint from over-
extension and limit excessive internal rotation of the tibia during flexion (Arnoczky 
and Marshall, 1977). In addition, there are two collateral ligaments on the medial and 
lateral side of the stifle joint. The medial collateral ligament passes distally from the 
medial femeral epicondyle, and inserts along the medial part of the tibia. The lateral 
collateral ligament originates on the lateral femoral epicondyle and passes distally to 
the insertion point on the fibular head (Canapp, 2007). These collateral ligaments are 
essential for the stability of the joints, chiefly in preventing the lateral displacement 
of their connecting bones  (Arnoczky et al., 1977).  
1.3.3 Synovial fluid 
The joint cavity is filled with synovial fluid, which is produced from the inner 
layer or synovial membrane of the joint capsule (Leeson et al., 1988). Normal synovial 
fluid is clear and light yellow being primarily composed of water and polymerised 
hyaluronic acid (Leeson et al., 1988). The function of synovial fluid is to act as a 
lubricant and to supply nutrients to articular cartilage and menisci (Clements, 2006). 
Mononuclear cells and neutrophils from the blood can penetrate through the 
synovial membrane helping remove normal degradative products of the articular 
cartilage and phagocytosing foreign material such as bacteria or fungi (Leeson et al., 
1988, Evans and Hermanson, 1993). Many enzymes found in synovial fluid have been 
used as biomarkers to determine joint disease in companion animals and humans 
(Hegemann et al., 2003, Catterall et al., 2010). Therefore, evaluating synovial fluid 
can be important in the examination of joint health (Clements, 2006). 
1.3.4 Intra-articular fat 
The infrapatellar fat pad (IPFP), also known as the Hoffa fat pad, is located 
between the between synovial membrane and the joint capsule within the knee joint 
(Saddik et al., 2004). It mainly covers the anterior part of the knee, just under the 
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patella (Saddik et al., 2004). IPFP has both protective and disease-enhancing effects 
in the knee joint (Ioan-Facsinay and Kloppenburg, 2013). For example, it functions as 
a local shock-absorber and a larger IPFP can reduce lateral tibial cartilage volume loss 
and knee pain in man (Teichtahl et al., 2015). On the other hand, IPFP primarily 
consists of adipose tissue, which is similar to SC adipose tissue and can secrete 
multiple inflammatory cytokines, adipokines and growth factors such as TNF-α, IL-1β, 
IL-6, leptin and vascular endothelial growth factor (Clockaerts et al., 2012). Moreover, 
chemical secreted from IPFP conditioned-medium and IPFP adipocyte themselve can 
induce dedifferentiated and inflammatory phenotypes in articular chondrocytes 
(Clockaerts et al., 2012, Chen et al., 2016). Therefore, it may play a role in the 
inflammatory processes in OA.  
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1.4 Anterior and cranial cruciate ligament disease 
1.4.1 Introduction 
In human, the anterior cruciate ligament (ACL) is the most commonly injured 
knee ligament susceptible to tears causing pain, joint instability and eventually 
degenerative joint disease (Griffin et al., 2000, Murray et al., 2013). An ACL injury can 
be a result of direct contact with an object to the lower extremity; however, it has 
been stated that up to 70% of ACL injuries result from noncontact (Boden et al., 
2000). Hundreds of thousands of ACL injuries occur in people every year, especially 
in athletes between 15 and 25 years of age (Griffin et al., 2006). ACL injury is the most 
common musculoskeletal injury predisposing to OA (Jomha et al., 1999, Brooks et al., 
2005, Alentorn-Geli et al., 2009). In the United States, at least 200,000 ACL 
reconstructions are performed each year with direct costs of approximately $3 billion 
annually (Brophy et al., 2009). ACL reconstruction surgery has also become a frequent 
procedure in the UK (Jameson et al., 2012). The aim of ACL reconstruction is to 
improve stability of a mechanically unstable knee but, unfortunately, it cannot 
protect against the development of post-traumatic OA and subsequent re-rupture of 
the ligament (Frosch et al., 2010). 
Animal models for the knee joint have been studied in various species 
including rabbit, dog, pig, sheep, and cow (Murray et al., 2013).  Arguably, the dog is 
most suitable because dog CCL is most like the human ACL in terms of histological 
appearance (Murray et al., 2004). Canine cranial cruciate ligament disease (CCLD) is 
a condition whereby progressive degeneration of the CCL leads to ligament rupture 
similar to non-contact injury in men (Grindstaff et al., 2006). Comparable to humans, 
CCLD is one of the most common causes of pelvic limb lameness in dogs, which has a 
huge economic impact for its treatment and management (Wilke et al., 2005, 
Witsberger et al., 2008) and increased in incidence over the last 40 years from 1.81% 
to 4.87% (Witsberger et al., 2008). The condition can also lead to consequent 
meniscal injuries and OA (Bennett and May, 1991, Vasseur and Berry, 1992). Micro-
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injury or mechanical loading has traditionally been attributed to traumatic CCL either 
complete or partial rupture (Griffon, 2010). However, most CCL ruptures in dogs 
occur spontaneously from progressive and irreversible degenerative alterations of 
the ligament itself (Hayashi et al., 2003, Lampman et al., 2003). Moreover, nearly 50% 
of dogs with CCLD will have their contralateral limbs develop CCL deficiency later in 
their life (Buote et al., 2009). 
1.4.2 Risk factors 
Risk factors for CCLD include genetics, poor limb conformation, age, 
reproductive status (being female and neutered), excessive exercise, greater 
bodyweight and obesity (Witsberger et al., 2008, Inauen et al., 2009, Ragetly et al., 
2011). There is a greater prevalence of CCLD in large breeds of dogs, such as Akitas, 
Labrador Retrievers, Mastiffs, Neopolitan Mastiffs, Newfoundlands, Rottweilers, 
Staffordshire Bull Terriers and St Bernards (Whitehair et al., 1993, Witsberger et al., 
2008, Adams et al., 2011), and a lesser prevalence in other breeds such as Basset 
Hounds, Dachshunds and old English sheepdogs (Whitehair et al., 1993, Duval et al., 
1999). Several genomic studies have identified chromosomal regions and genetic 
markers which may play a role in non-traumatic canine CCLD particularly in breeds 
such as the Newfoundland (Wilke et al., 2009, Baird et al., 2014). Poor conformation 
of the pelvic limb could also predispose to the risk of CCL deficiency (Inauen et al., 
2009, Mostafa et al., 2010). In these studies, dogs with a greater inclination of the 
proximal tibia relative to the distal tibial axis, as well as dogs with a small tibia 
tuberosity, are predisposed to CCL deficiency because of excessive rotational forces 
placed on the CCL during weight bearing (Inauen et al., 2009, Mostafa et al., 2010). 
In addition, many studies have shown that older dogs tend to develop CCLD 
compared to those of a younger age (Witsberger et al., 2008, Adams et al., 2011). In 
terms of reproductive status, female dogs and neutered dogs are more likely to have 
CCLD (Whitehair et al., 1993, Adams et al., 2011). Furthermore, many demographic 
studies have demonstrated that CCLD is frequently seen in dogs that are overweight 
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or have obesity up to 4-fold (Whitehair et al., 1993, Brown et al., 1996, Diez and 
Nguyen, 2006, Adams et al., 2011). 
1.4.3 Aetiopathogenesis for CCLD 
Mechanical injury may not be the only reason for CCLD, with other 
mechanisms implicated such as immune-mediated disease, inflammatory cytokines 
and enzymes (Cameron et al., 1994, Lawrence et al., 1998, Lemburg et al., 2004, Muir 
et al., 2006, Erne et al., 2009). Pro-inflammatory cytokines are implicated in the 
pathogenesis of human ACL because IL-1, IL-6, IL-8 and TNF-α, concentrations are 
increased in the synovial fluid of the knee joint in people with ACL injury (Cameron 
et al., 1994, Irie et al., 2003). However, it is not known whether these cytokines are 
secondary consequence of ligament injury or might itself be an inciting cause of 
ligament degeneration (Comerford et al., 2011). Matrix metalloproteinases (MMPs)-
1, -2, -3, -9, -13 all play important roles in matrix degradation; all of these have been 
associated with the development of OA and are also reported to be the most 
influential MMPs in CCLD (Comerford et al., 2004, Muir et al., 2005, Sardari et al., 
2011, Boland et al., 2014, Haslauer et al., 2014). Increased collagen and 
glycosaminoglycan (sGAG) synthesis in the extracellular matrix of ruptured CCLs, 
together with increased sGAG concentration in synovial fluid of dogs with CCLD have 
been demonstrated (Arican et al., 1994, Comerford et al., 2004). This suggests that 
there is increased matrix turnover and degradation within the ligament tissue prior 
to or following rupture. 
1.4.4 Clinical assessment of canine CCLD 
1.4.4.1 Orthopaedic examination  
A thorough orthopaedic examination includes palpation and manipulation of 
all joints, conformation evaluation and gait assessment (Malikides et al., 2007). CCLD 
leads to stifle joint instability due to several types of mechanoreceptors found within 
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the CCL (Georgoulis et al., 2001) .Palpation of the stifle joint should be performed to 
determine joint effusion )Jerram and Walker, 2003 ( . Periarticular thickening around 
the medial surface of the joint, also known as the buttress sign, is often seen and is 
believed to be associated with chronic meniscal injury (Piermattei et al., 2006). 
Palpation of both pelvic limbs can also be used to identify muscle atrophy in 
comparison with the contralateral limb (Jerram and Walker, 2003). The cranial 
drawer sign, using direct (cranial drawer test) and indirect (tibial compression test) 
palpation techniques can provide a definitive diagnosis for CCLD (Piermattei et al., 
2006), where the tibia can be displaced cranially (Moore and Read, 1996a).  
With partial CCL rupture, a dog presenting with hind limb lameness but no 
obvious drawer sign is a common situation. Synovial fluid analysis, computed 
tomographic arthrography and magnetic resonance imaging should be considered to 
evaluate joint inflammation, and to help diagnose the damage of cruciate ligament 
fiber (Faldyna et al., 2004, Han et al., 2008, Erne et al., 2009, Sample et al., 2017). 
1.4.4.2 Subjective lameness evaluations 
Dogs with CCLD typically show pelvic limb lameness due to pain and instability 
in the associated stifle joint (Jerram and Walker, 2003). Dogs with CCLD may also have 
meniscal tears at the time of injury but this can also occur later, leading to pain and 
increased lameness (Wustefeld-Janssens et al., 2016). The severity of lameness can 
vary from non-weight-bearing to intermittent, depending on the time since injury 
and degree of damage to the CCL and menisci (Piermattei et al., 2006). There are 
several subjective and objective methods to assess severity of lameness in dogs 
(DeCamp, 1997, Lane et al., 2015). However, a numerical rating scale system and a 
continuous scale are commonly used in general practice because it is convenient and 
repeatable (Hudson et al., 2004, Mathews et al., 2014). Veterinarians can easily use 
this system to grade degree of lameness into categories from 0 (clinically sound) to 5 
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points or 10 points (continuous non-weight bearing) when viewing the dog at a walk 
and trot (Vasseur and Slatter, 1993, Malikides et al., 2007, Mathews et al., 2014).  
1.4.4.3 Objective lameness evaluation  
Objective observations of gait analysis, such as kinetic (force plate analysis) 
and kinematic evaluation (computer-assisted three-dimensional analysis, 
electromyography) are more reliable than visual gait assessment since they eliminate 
human observer bias (Quinn et al., 2007). These objective measurements of limb 
function are the gold standard for determining lameness (DeCamp, 1997, Gillette, 
2004). Many veterinary orthopaedic studies, including those on canine CCLD, have 
used force plate analysis for assessing lameness (Ballagas et al., 2004, Brown et al., 
2013). A normal gait cycle includes a stance phase, which is the period when the foot 
is in contact with the ground, and a swing phase where the foot is in the air (DeCamp, 
1997). During each stance phase, force plates connected to computers quantify the 
three orthogonal ground reaction forces (GRFs) as the dog walks over the plate, 
which include vertical (Fz), craniocaudal (Fy) and mediolateral (Fx) forces (Figure 
1.2A). These forces are then generated into pressure graphs on a computer screen 
for each strike and can be used for analysis with specific software (Figure 1.2B) 
(DeCamp, 1997, Gillette and Angle, 2008). Fz most directly measure weight-bearing, 
have the greatest magnitude compared with other orthogonal forces and are good 
parameters for asymmetry assessment of left and right limbs (DeCamp, 1997, 
Fanchon and Grandjean, 2007). Therefore, Fz variable such as peak vertical force 
(PVF), vertical impulse (VI), rising slope (RS) and falling slope (FS) as well as symmetry 
or asymmetry indices (AI) have been used for detection of pelvic limb lameness in 
dogs (Fanchon and Grandjean, 2007). At walk, the first peak of Fz corresponds to the 
PVF allied with the initial paw strike in early stance and the second peak, if present, 
represents maximal vertical forces generated in late stance associated with toe-off 
or propulsion (DeCamp, 1997) (Figure 1.2B). At trot, Fz in the dog are graphed as 
single, sharper peaks for both forelimbs and rear limbs, because the stance phase 
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happens more quickly (Figure 1.2c). Obese dogs normally have greater PVF and 
horizontal GRFs than lean dogs (Brady et al., 2013). PVF and VI are the most 
commonly used parameters measured in the assessment of pelvic limb lameness in 
veterinary orthopaedic studies. These parameters are reduced in value in dogs with 
CCLD or when lameness is present (Budsberg et al., 1988, Jevens et al., 1996, Ballagas 
et al., 2004, Voss et al., 2008).  
RS is defined as the slope of the straight line that connects the beginning of 
the stance phase to the first peak and represents the rate at which a dog loaded the 
limb on the plate. Conversely, FS is defined as the slope of the straight line that 
connects the peak to the end of the stance phase which represents the rate at which 
the dog unloads the limb off the plate (Evans et al., 2005). Pelvic limb lameness 
usually causes a reduction in mean rising slope and an increase in mean FS (Budsberg 
et al., 1988, Budsberg et al., 1996). 
In healthy dogs, there is no significant asymmetry between the 2 body sides 
of locomotion detected during walking and trotting (Budsberg et al., 1993, Fischer et 
al., 2013). Conversely, when lameness is present, the load decrease in the injured 
limb and the compensatory load increase in the contralateral limb results in an 
alteration in limb symmetry (Böddeker et al., 2012, Fischer et al., 2013). Therefore, 
the parameters from force plate measurement can help in the investigation of 
abnormalities in a step cycle of gait, and are also useful in assessing medical or 
surgical treatment outcomes (Voss et al., 2008, de Medeiros et al., 2011, Vassalo et 
al., 2015). 
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A   
B   
C   
Figure 1.2 Kinetic force plate analysis of limb function. 
Figures show three orthogonal ground reaction forces; vertical (Fz), craniocaudal (Fy) and 
mediolateral (Fx) are detected as the dog steps on a force plate (A). The force reactions of 
two limbs; the left graph and the right graph display forces from a pelvic limb and a thoracic 
limb at walk (B) and at trot (C). The blue, the green and the red line represent data points 
associated with Fz, Fy and Fx force respectively. 
Fz 
Fy 
Fx 
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1.4.4.4 Radiographic assessment of the stifle joint 
Imaging of the canine stifle joint using radiography is helpful for assessing the 
affected joint, to evaluate severity of OA secondary to CCLD and to exclude other 
musculoskeletal abnormalities such as fractures and/or neoplasia (Jerram and 
Walker, 2003, Böddeker et al., 2012). Common radiographic findings in cases of CCLD 
include muscle atrophy, joint effusion, periarticular swelling and periarticular 
osteophyte formation (Piermattei et al., 2006). In rare cases, ligament avulsions can 
be seen (Piermattei et al., 2006). Previous studies have shown that CCLD results in 
stifle joint instability and initiated the development of stifle OA (Vasseur and Berry, 
1992). OA pathogenesis is characterised by an increased thickness of the subchondral 
bone, destruction of articular cartilage, osteophyte formation, synovial hyperplasia 
and fibrosis of the joint capsule (Gilbertson, 1975, Dedrick et al., 1993). Therefore, 
radiographic grading systems have been developed for the canine stifle joint and 
have been regularly performed in CCLD cases to evaluate degeneration of the joint 
(Innes et al., 2004, Lazar et al., 2005). Other imaging techniques used in the diagnosis 
of meniscal disease include ultrasonography, magnetic resonance imaging, plain and 
contrast computed tomography and arthroscopy (Gnudi and Bertoni, 2001, Barrett 
et al., 2009, Samii et al., 2009, Plesman et al., 2013). However, these modalities 
require specialist equipment and skilled operators, which can result in low specificity 
and sensitivity (Bergman et al., 2007). 
1.4.5 Treatment of CCLD 
There are several factors that veterinarians must consider when selecting the 
most appropriate treatment option for canine CCLD including severity of lameness, 
age, bodyweight and the equipment available along with expertise in its use 
(Comerford et al., 2013, Duerr et al., 2014). The aims of treatment are to improve 
stability and to try and restore the normal functions of the stifle joint (de Rooster et 
al., 2006). Treatment options for CCLD included conservative and surgical 
management (Jerram and Walker, 2003). Conservative management is reportedly a 
reasonable option for managing CCLD in dogs under 15 kg bodyweight (Comerford et 
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al., 2013), and options include controlled weight loss, the administration of analgesic 
medications, physiotherapy and rest. There are many surgical techniques for 
managing CCLD including extra- and intra-capsular techniques and tibial osteotomies 
such as tibial plateau levelling osteotomy (TPLO), tibial tuberosity advancement 
(TTA), and triple tibial osteotomy (TTO) (Innes, 2012, Bergh et al., 2014, Knebel and 
Meyer-Lindenberg, 2014). However, despite a range of surgical methods, the most 
effective treatment for CCLD remains controversial because none of them have been 
found to be effective in stabilising the joint and minimising the degeneration of the 
joint (Lazar et al., 2005, Krotscheck et al., 2016). Extracapsular stabilisation methods 
have been recommended for use in small breed dogs (Duerr et al., 2014); however, 
there is little good quality evidence to suggest that these techniques do not work in 
larger dogs (Chauvet et al., 1996). Such techniques involve the use of heavy-gauge 
suture such as leader line nylon or fibre wire to decrease joint instability by attaching 
with soft or bony tissues (Cook et al., 2010). Intracapsular procedures substitute the 
function of the ruptured CCL with an autograft, allograft, xenograft or synthetic 
materials; however, these techniques have not been shown to be effective (Person, 
1987, Moore and Read, 1996b). TPLO is one of the most common surgical methods 
for CCLD management in large and small breed dogs (Duerr et al., 2014). Unlike in 
man, the canine tibial plateau has an increase slope on cranial part; so the purpose 
of an osteotomy is to level it (Slocum and Slocum, 1993). TPLO aims to make the tibial 
plateau perpendicular to the long axis of the tibia. Therefore, neutralise the 
mechanical forces acting on the stifle, rendering the cranial cruciate ligament 
unnecessary (Kowaleski and McCarthy, 2004).  
The TTA is a less invasive surgery and gives similar outcomes to the TPLO 
(Duerr et al., 2014). The procedure involves making a cut in the front part of the tibial 
tuberosity and advancing this portion of bone forward. The tibial tuberosity is 
secured with specially designed implants so that the angle of the patellar ligament 
approaches 90 degrees to the tibial slope and the opposing forces become 
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eliminated. Thus, the tibia bone remains in place when weight is placed on the limb 
(Lafaver et al., 2007).  
1.4.6 Post-operative management and assessment of CCLD 
Post-operative management and follow-up examination for CCLD are 
important in overall treatment outcome. Several studies have indicated that 
controlled weight loss significantly improves clinical signs and limb function of dogs 
with CCLD and OA (Impellizeri et al., 2000, Mlacnik et al., 2006, Wucherer et al., 
2013). Therefore, educating clients of overweight dogs about weight loss should be 
considered both pre- and post-management for CCLD (Innes, 2012). In terms of 
exercise programmes as post-surgical management of CCLD, some veterinarians are 
hesitant to promote early use of the limb and instead advise exercise restriction 
(Comerford et al., 2013). However, excessive immobility of the joint could cause 
adverse biochemical and metabolic changes in articular cartilage (Keller et al., 1994). 
Recent studies have shown a well-designed and frequent rehabilitation programme 
performed in the initial post-operative period was safe and encouraged rapid return 
to normal limb function for dogs (Marsolais et al., 2002, Romano and Cook, 2015). In 
general, a complete clinical orthopaedic examination, mediolateral and caudocranial 
radiographs of the operated stifle joint are performed during the follow-up 
examinations at 6 to 8 weeks depending on which surgical option has been used 
(Jerram and Walker, 2003). Kinetic and kinematic gait analyses are also 
recommended for assessing return of joint function at this first follow-up if accessible 
(DeCamp, 1997, Voss et al., 2008). A minimum long-term follow-up time of 6 months 
is suggested; whilst longer-term follow-up could also be important (Bergh et al., 
2014). This is because alteration of biomechanics within the stifle joint after surgical 
intervention may have long-term effects on eventual clinical outcomes (Bergh et al., 
2014).
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1.5 Link between adipokines and joint diseases 
Obesity is suggested to be a risk factor for musculoskeletal injuries in humans 
(Heir and Eide, 1996), and especially lower extremity joint disorders (Andriacchi et 
al., 2004), with the excess bodyweight from obesity causing increased mechanical 
loading.  Indeed, the risk for knee injury increases with increasing BMI in humans 
(Sulsky et al., 2000, Webb et al., 2004, Mattila et al., 2007); obese men (BMI > 30) 
have a threefold higher risk of medial and lateral collateral ligaments tears (Sillanpaa 
et al., 2008), a twofold increase in the risk for patellar dislocation (Kuikka et al., 2013), 
and an increase in the incidence of the medial meniscal tear compared with 
overweight men with lower BMI (Ozkoc et al., 2008). 
However, several human studies have also identified obesity as an 
independent risk factor in non-weight-bearing joints such as the hand and upper 
extremity soft tissue (Carman et al., 1994, Cicuttini et al., 1996, Dahaghin et al., 2007, 
Rechardt et al., 2013). Other studies have shown that some joint diseases such as 
rheumatoid arthritis (RA) and OA are associated with both adipose mass and central 
adiposity (Otero et al., 2006, Wang et al., 2009). Moreover, it has been shown that a 
reduction in body fat is more advantageous than body mass loss in relieving of OA 
progression (Toda et al., 1998). Therefore, it is suggested that other mechanisms 
rather than increased mechanical loading might be responsible for the adverse effect 
of adipose tissue in musculoskeletal disease. For example, as discussed above, 
adipose tissue is a major source of adipokines and inflammatory cytokines, and these 
might instead be provoking cartilage and articular tissue degeneration (Doom et al., 
2008, McNulty et al., 2011). In this respect, recent studies have demonstrated that 
the IPFP is a main source of adipokines and cytokines produced in human knee 
(Ushiyama et al., 2003, Presle et al., 2006, Klein-Wieringa et al., 2011). Further, gene 
expressions of leptin and visfatin are increased in the IPFP in mice fed on a high fat 
diet and are correlated with expression of inflammatory cytokines such as TNF-α in 
the IPFP (Iwata et al., 2013). Serum leptin concentration in mice fed with a high-fat 
diet increase with OA severity, whereas mice with leptin deficiency can be morbidly 
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obesity but have no signs of OA (Griffin et al., 2009, Griffin et al., 2010). These studies 
suggest that adipokines might have local effects in the development of joint 
inflammation and degeneration. 
In human, adiponectin, leptin and visfatin are also implicated in different joint 
diseases such as OA and RA (Lago et al., 2007a). Recent investigations into the role of 
adipokines in the development of OA have demonstrated that plasma adiponectin 
concentration and adiponectin released from knee cartilage of OA patients are 
positively correlated with their knee radiographic scores (Koskinen et al., 2011). 
Moreover, adiponectin also induces production of nitric oxide, IL-6, MMP-1 and 
MMP-3 in primary chondrocytes and in OA cartilage in vitro (Koskinen et al., 2011). 
Gene expression and protein concentration of leptin in osteophytes, cartilage and 
synovial fluid from patients with knee OA are found to be higher than in a healthy 
control group (Dumond et al., 2003, Ku et al., 2009). One study demonstrated an 
association of leptin concentration in synovial fluid and the radiographic severity of 
knee OA (Ku et al., 2009), whilst a second study suggested that the adiponectin-to-
leptin ratio in synovial fluid could predict knee pain in subjects with knee OA (Gandhi 
et al., 2010). Leptin is reported to have a catabolic effect on chondrocyte metabolism 
by inhibiting chondrocyte development, inducing production of pro-inflammatory 
cytokine (IL-1) and up-regulating expression of matrix metalloproteases such as 
MMP- 9 and -13 (Gualillo, 2007, Simopoulou et al., 2007, Hui et al., 2012).  
In addition, a study on RA has found evidence of increased adiponectin, leptin, 
and visfatin concentration in plasma of the patients (Otero et al., 2006). The 
concentrations of visfatin in serum and synovial fluid have also been found to be 
correlated with radiographic joint damage, degree of inflammation and matrix-
degrading activities in the joints of RA patients (Brentano et al., 2007, Rho et al., 
2009). A recent study has also shown that visfatin may promote the catabolic 
degradation of both cartilage and meniscus in vitro (McNulty et al., 2011). From this 
evidence, it is suggested that adiposity in the body may have biological effects on 
joint degeneration (Wang et al., 2015). However, local adipokines produced from 
43 
 
intra-articular fat are considered as humoral factors that can contribute to the 
development and progression of various joint diseases such as in OA and RA 
(Toussirot et al., 2007).  
An increased fat mass and percentage of fat of lower extremity has been 
observed in patients with unilateral ACL disease as compared to the intact lower 
extremity (Takata et al., 2007). In dogs, obesity has been described as a risk factor for 
CCLD (Adams et al., 2011). Joint inflammation induced by biochemical factors such as 
cytokines has been implied in CCLD (Erne et al., 2009). Nonetheless, the precise 
mechanisms underlying the association between humoral effect of obesity and CCLD 
have not yet been clarified. In this regard, studying the role of adipokines in canine 
CCLD may be essential in developing future preventative strategies and management 
of this condition in the dog and may act as a relevant model for human disease. A 
better understanding of the disease mechanisms would also enable us to possibly 
target the degenerative ligament processes, which may lead to a reduction in the 
incidence of non-contact cruciate rupture and OA in both dogs and humans.
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1.6 Hypothesis and Aims 
1.6.1 General Hypotheses 
The hypotheses of the study are that both systemic and local (intra-articular 
stifle joint tissues) cross-talk occur between adipokines and articular tissue in obese 
dogs and that mechanisms can play a role in the pathophysiology of CCLD. 
1.6.2 Aims 
To answer these hypotheses, this study aimed to: 
 Investigate the relationship between mechanical (bodyweight) and humoral 
(body fat composition) factors of obesity and clinical presentation of dogs with 
CCLD. 
 Examine differences in gene expression of pro-inflammatory cytokines, tissue 
degradation biomarkers, and adipokines in dogs with and without CCLD. 
 Determine the association of both local and systemic adipokines with pro-
inflammatory cytokines and tissue degradation biomarkers in CCL tissues and 
synovial fluid of dogs with CCLD. 
 Investigate the relationship between chemical mediators in synovial fluid and 
CCL tissues of the stifle joint and clinical presentation in dogs with CCLD. 
 Examine cross-talk between adipose tissues (both systemic and local) and CCL 
tissues on CCL explants in terms of glycosaminoglycan production using co-
culture systems.  
 Examine the effects of adipokines (adiponectin, leptin, and visfatin) on CCL cells 
in relation to cartilage degradation biomarkers gene expression, cells viability 
and cells migration activities.
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Chapter 2 Materials and Methods 
2.1 Animals 
2.1.1 Control group 
Dogs that had been euthanased for reasons other than musculoskeletal 
disease were used as a control group. Ethical permission for using such material was 
provided following local institutional ethical review (RETH0000553 and VREC213). 
Signalment information including dog breed, sex, age and bodyweight were 
collected. Samples including synovial fluid, cranial cruciate ligaments (CCLs), 
infrapatellar fat pad (IPFP) were harvested from the right stifle joint and 
subcutaneous (SC) fat from the inguinal area of cadaveric dogs within 24 hours of 
death. Tissues were either snap-frozen in liquid nitrogen, and stored at -80°C until 
further analysis or processed immediately for tissue culture and cell isolation. 
2.1.2 Clinical group 
The clinical group for this study comprised dogs diagnosed with cranial 
cruciate ligament disease (CCLD) referred to the Small Animal Teaching Hospital, 
University of Liverpool. CCLs were obtained at surgical intervention for the 
management of CCLD in affected dogs. 
Dogs were excluded if they had bilateral CCLD, lumbosacral disease or pain in 
any other pelvic limb joints. Fully informed written consent was obtained from all 
owners who allowed their dogs to be recruited in this study. Ethical permission for 
using these samples was granted following local institutional ethical review 
(VREC192). Signalment data including dog breed, sex, age and bodyweight were 
obtained from clinical records. Synovial fluid and tissues including ruptured CCLs, 
IPFP, SC were also collected from the clinical dog group at the time of 
arthroscopy/arthrotomy. Tissues were either snap-frozen in liquid nitrogen, and 
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stored at -80°C until further analysis or processed immediately for tissue culture and 
cell isolation. 
2.2 Body condition score evaluations in control and clinical 
groups 
Body condition score (BCS) was recorded for all animals in both groups. The BCS for 
each dog was assigned by two investigators, Wipawee Saengsoi (WS) and Alex 
German (AG), using a modification of the 9-point system based on size of dogs and 
images in specific category (Laflamme, 1997b). This system describes the body 
condition of dogs with values between 1 and 9; where BCS scores of 1-3 points are 
too thin, 4-5 being ideal, 6-7 being overweight and 8-9 being obese (see Appendix 1 
and Chapter 1 Section 1.1.4). 
2.3 Diagnostic investigations and body fat composition 
measurements in the clinical group 
2.3.1 Lameness score 
Subjective lameness scores were graded to all dogs with CCLD by an ECVS 
resident or RCVS or ECVS Diploma holding orthopaedic surgeon from the Small 
Animal Teaching Hospital orthopaedic service using a Likert scale of 0 – 10. This scale 
ranges from 0 (sound at all times) to continuous, non-weight bearing lameness being 
10 (Vasseur and Slatter, 1993). 
2.3.2 Force plate measurement 
Objective measurements of lameness were determined using kinetic gait 
analysis as previously described (Chapter 1 Section 1.4.4.3). Gait analysis was 
performed immediately pre-operatively. Dogs were walked at an average speed of 
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1.0-1.3 m/s over a force platform (Kistler, Winterthur, Switzerland) situated in the 
middle of a 10-metre runway. Data including peak vertical force (PVF), vertical 
impulse (VI), falling slope (FS), together with asymmetry indices of these values were 
collected electronically using Qualisys QTM (Gothenburg, Sweden) and Bioware 
(Kistler) software. Five replicates of these parameters were analysed in a computer 
spreadsheet (Excel, version 14.0.6106.5005, Microsoft Office Professional Plus 2010) 
(Evans et al., 2005, Fanchon and Grandjean, 2007). Synchronised digital video files 
were also collected and stored to validate each dog’s gait cycle.  
2.3.3 Radiographic examination and score 
Orthogonal radiographic views (mediolateral and caudocranial) were 
obtained under sedation in all dogs in the clinical group to confirm the diagnosis of 
CCLD as well as for surgical planning. Radiographic scores were determined by 
examination of the mediolateral and caudocranial views (see Appendix 2) of the index 
stifle joint according to a 5-point Likert system, with 0 representing no osteophytosis 
and 4 representing the most severe osteophytosis (Innes et al., 2004). Radiographic 
views were independently scored twice by two blinded investigators, WS and Eithne 
Comerford (EC), at least two weeks apart.  
2.3.4 Dual-Energy X-Ray Absorptiometry (DEXA) 
To determine body fat composition, each dog was scanned using a fan-beam DEXA 
scanner (Lunar Prodigy Advance, GE Lunar, Madison, USA) while the dogs were 
sedated for radiographic examination (Section 2.3.3) or prior to surgical management 
for CCLD. The scanner performed a single sweep, with the dog positioned in dorsal 
recumbency on the scanner table (Figure 2.1A). A whole-body scan was generally 
completed in 4-6 minutes depending on the dog’s breed. The manufacturer’s 
software (enCORE 2004, 8.70.005; GE Lunar) was then used to analyse the resulting 
images (Figure 2.1B).
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A            B   
Figure 2.1 Dual-energy X-ray absorptiometry (DEXA) scanning. 
Figures show a dorsal recumbency position of the dog during DEXA scanning (A)  and a 
typical example of an image obtained from the scan (B). In figure B, lines determine regions 
of interest used to calculate body fat mass, grey areas show air and white areas show 
muscle, fat and bone. 
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2.4 Tissue culture 
2.4.1 Tissue explant culture 
CCL (approximately 50 mg), IPFP (approximately 150 mg) and SC 
(approximately 150 mg) explants were dissected from the whole tissue samples 
collected from control and clinical dogs (as described in Section 2.1.1-2.1.2). Explants 
were cultured in five different groups; CCL, IPFP, SC, CCL+IPFP, CCL+SC, in complete 
media containing Dulbecco’s Modified Eagle’s Medium (Gibco®, Life Technologies, 
MD, USA), 10% foetal bovine serum (FBS, Sigma-Aldrich), 100 U/ml penicillin-
streptomycin (Gibco®) and 2 μg/ml amphotericin B (Gibco®). Media from the culture 
were collected and replaced every 3-4 days. 
2.4.2 Cell isolation 
Fresh CCL samples were collected and transported to the laboratory within 
about 30 minutes (as described in Section 2.1.1-2.1.2). The sample was placed in a 
Petri dish and finely chopped using a number 20 disposable scalpel before being 
transferred into a 15-ml falcon tube containing freshly prepared digestion medium 
which contained collagenase type II (Worthington Biochemical Corporation, 
Lakewood, USA) in complete media (as detailed in Section 2.4.1) at a concentration 
1 mg/ml. This digestion medium was sterilised by filtrating it through a 0.2 μm 
disposable filter. The tube was shaken horizontally in a 37˚C incubator at 170 
cycles/minute for 16 hours to digest the tissue (Hwang et al., 2010). After 16 hours, 
undigested material was removed by passing it through a cell strainer followed by 
centrifugation (200 x g for 10 minutes) to obtain a cell pellet allowing the supernatant 
to be removed and discarded using a pipette. The cell pellet was re-suspended in 10 
ml of sterile of complete media (as described in Section 2.4.1) followed by 
centrifugation twice, as detailed above, to wash the cells. Cell count was determined 
using a haemocytometer (Agar Scientific, Essex, UK) and cells were then seeded into 
a T75 flask at a density of 2.1 x 106 cells per flask. Complete media was added to the 
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flask making up to a final volume of 15 ml. The cells were kept in an incubator (Sanyo 
Electric Biomedical, Osaka, Japan) at 37°C in a >98% humidified, 95% air and 5% CO2 
atmosphere. 
2.4.3 Maintenance of CCL cells 
Primary canine CCL cells were maintained with a complete media (as 
described in Section 2.4.1) change every 2-3 days until cells reached 80% confluence. 
For propagation, medium was removed, and the cell layer was washed with 
phosphate buffered saline (PBS). PBS was removed and 5 ml of 0.05% trypsin in 0.53 
mM EDTA (Gibco®) was then added into T75 flask to detach the cells. The cells were 
incubated at 37°C for five minutes, or until all cells had detached from the flask. An 
equal volume of serum-containing cell culture medium was next added to stop the 
cell detachment procedure. After counting the suspended cells with a 
haemocytometer, cells then were distributed into new flasks for continued expansion 
or into 24-well plates (10,000 cells/cm2) for use in future experiments. All cells used 
in experiments were at the second or the third passage.  
In order to freeze cells for future use, cell suspensions were transferred into 
a 15-ml falcon tube and centrifuged at 200 x g for 10 minutes. Supernatant was 
removed from pellet; the cell pellet was then re-suspended in cell culture medium 
and the centrifugation repeated. The cell pellet was then re-suspended in complete 
medium containing 10% v/v dimethyl sulfoxide (DMSO, Sigma-Aldrich). The cell 
suspensions (1 ml) were distributed into 1.5-ml cryogenic vials. The vials were put in 
a cell freezing container (CoolCell®, Biocision, Larkspur, USA) at -80°C overnight 
before transferring to the -80°C freezer until required. 
2.4.4 Cell viability assay 
CCL cell viability was analysed using CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega) according to the manufacturer’s protocol. This assay determines the 
number of viable cells in culture based on quantitation of the ATP present (Lovborg 
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et al., 2002). Briefly, thawed CCL cell samples were cultured in a 96-well flat-bottom 
white tissue culture plate (VWR, Radnor, USA). at 3,000 cells per well (8,824 
cells/cm2). Cells were treated in triplicate with different concentrations (10 and 50 
ng/ml) of recombinant human adiponectin, recombinant human leptin and 
recombinant human visfatin (Peprotech, Rocky Hill, USA). Cells treated with a toxic 
dose 200 μg/ml of lipopolysaccharide (Sigma-Aldrich) were used as positive controls 
(Sharifi et al., 2010) and untreated cells as negative controls. Background 
luminescence was determined using wells containing medium without cells. After 
incubation of the cell cultures for 48 hours at 37°C in a >98% humidified, 95% air and 
5% CO2 atmosphere, the culture media in each well was replaced with 100 μl of fresh 
complete media and topped up with 100 μl with CellTiter-Glo® reagent using a 
multichannel pipette. The contents were mixed on a plate shaker for two minutes 
and incubated at room temperature for ten minutes. Luminescence was then 
recorded using a GloMax® Multi+ Detection System (Promega) (Riss et al., 2004, Niles 
et al., 2009). 
2.4.5 Cell migration assay 
For this assay, a protocol developed by Dr. Christopher Mendias’s laboratory 
(Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, USA) was 
followed based on a collagen gel technique (Hotary et al., 2000, Hudgens et al., 2016). 
Briefly, type I collagen, derived from rat tail tendons (kindly provided by Dr.Mendias), 
was dissolved in 0.2% acetic acid at a final concentration of 2.7 mg/ml at 4°C 
overnight. To induce gelling, collagen was mixed with 10X MEM (Minimum Essential 
Medium, Gibco®) and 0.34 N NaOH in an 8:1:1 ratio on ice and 350 μl of this mixture 
was added to the upper well of 12-mm transwell plates (3-μm pore size; Corning®, 
Sigma-Aldrich). The plates were placed in the incubator at 37°C for one hour. After 
the gels were set, 1x104 CCL cells in 300 μl of complete medium (prepared with 10% 
heat-inactivated FBS) were added to the upper wells. A further 1.5 ml of complete 
medium was also added to the lower compartment of the transwell chambers. After 
an additional 24-hour incubation period, to allow cells to acclimatise, 20 ng/ml of 
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recombinant human platelet-derived growth factor (PDGF-BB, R&D Systems) was 
added to initiate cell migration as positive controls and/or 10 ng/ml of adipokines 
(adiponectin, leptin and visfatin) were added to the cultures. These factors were 
introduced into the lower compartment of the transwell chambers (Figure 2.2). The 
medium and chemical reagents were replaced every 2-3 days for 7 days. The collagen 
gels were then fixed with 4% paraformaldehyde and paraffin-embedded. Sections of 
the collagen gel were cut at 7 μm, mounted on microscope slides and stained with 
haematoxylin and eosin (Feldman and Wolfe, 2014). The percentages of migrating 
cells and maximum migrated distance were quantified under a microscope as the 
mean ± S.E from five different fields of each gel.
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Figure 2.2 Cell migration experiment template. 
Cultures of CCL cells isolated from control and clinical dogs (sample 1 -  3)  were exposed to 
10 ng/ ml of adipokines; adiponectin, leptin and visfatin.  20 ng/ ml of recombinant human 
PDGF-BB (PDGF) was used as a positive control. 
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2.4.6 Glycosaminoglycan measurement 
Spectrophotometric assays, based on the colour reaction with 1,9-
dimethylmethylene blue (DMMB), were used to measure the glycosaminoglycan 
(sGAG) content in control and clinical tissues (Farndale et al., 1982, Homer et al., 
1993). After 14 days of culture, tissue samples were weighed and digested, with 10 
units/ml of papain (Sigma-Aldrich) in 100 mM sodium acetate, 2.4 mM EDTA, 5mM 
L-cysteine, pH 5.8 in a sufficient volume just to cover the samples in 1.5 ml centrifuge 
tubes, overnight at 60 °C. The samples were vortex mixed several times during 
digestion to ensure complete digestion. After tissue digestion method, CCL in papain 
suspension was diluted 1:10 in deionised water before measuring to ensure sGAG 
concentrations were within the linear range of the assay. DMMB dye was prepared 
from 1 L deionised water containing 16 mg DMMB (Sigma-Aldrich), 2 g sodium 
formate and 2 ml formic acid (Merck, Darmstadt, Germany) at pH 3.5. Then 250 µl of 
DMMB dye was added to 40 µl of papain digestions or media samples in 96-well 
plates. Absorbance of the resulting solution was immediately measured using a plate 
reader (Multiskan FC, Thermo Scientific) at 570 nm. sGAG concentration in each well 
was calculated by comparison to chondroitin sulphate standards (prepared from 
shark chondroitin sulphate C, Sigma-Aldrich) in the concentration range of 0 – 70 
µg/ml (Figure 2.3), and sGAG concentration was expressed as μg per mg dry weight 
tissue.  
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Figure 2.3 Glycosaminoglycan standard curve. 
The glycosaminoglycan standard curve generated from the absorbance of 
chondroitin sulphate in the concentration range of 0 – 70 µg/ml after their 
reaction with 1,9-dimethylmethylene blue.  
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2.5 Measurement of the gene expression and protein 
concentration of cytokines and adipokines in control and 
clinical groups 
2.5.1 Measurement of gene expression 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was 
used to determine gene expression for interleukin-6 (IL-6), macrophage chemotactic 
protein-1 (MCP-1), tumour necrosis factor-α (TNF-α), aggrecan (AGC), type I collagen 
alpha two chain (COL1A2), matrix metalloproteinase-13 (MMP-13), adiponectin, 
leptin, and visfatin in tissue samples as described in Section 2.1.  
  
  
 
5
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             Table 2.1 List of primer sequences used for target genes as designed using Eurogentec, Seraing, Belgium. 
Gene Final concentration (nM) Forward Primer Sequence (5’-3’) Reverse Primer Sequence (5’-3’) 
β-actin 300 GCATCCTGACCCTCAAGTACC AGCTCGTTGTAGAAGGTGTGG 
RPS-13 300 GCAGATCTACAAACTGGCCAAGA TGCAACACCATGGGAGTCTCT 
IL-6 600 AAAGAGCAAGGTAAAGAATCAGGATG GCAGGATGAGGTGAATTGTTGTG 
MCP-1 600 TCCTCTGCCTGCTGCTCATAG GGCCAGCCTCTGAATTGAGATC 
TNF-α 300 CCGTGAGAAGATGACCCAGATC GACAGCACAGCCTGGATGG 
AGC 300 GGGACCTGTGTGAGATCGAC GTAACAGTGGCCCTGGAACT 
COL1A2 300 CTATCAATGGTGGTACCCAGTTT TGTTTTGAGAGGCATGGTTG 
MMP-13 300 CCGCGACCTTATCTTCATCT AACCTTCCAGAATGTCATAACCA 
Adiponectin 600 CCGTGATGGCAGAGATGGC AGCCTCGGGGACCTTCAAC 
Leptin 600 AGGATCAATGACATTTCACACACG GGACAAACTCAGGACTGGTTGG 
Visfatin 300 AAGGCCTGTACTGCAATTTTATATGTC GGAAGCAGAAATTCTCTCTAAAAACATC 
RPS-13: ribosomal protein S13; IL-6: interleukin-6; MCP-1: macrophage chemotactic protein-1; TNF-α: tumour necrosis factor-α; AGC: 
aggrecan, COL1A2: type I collagen; MMP-13: matrix metalloproteinase-13. 
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2.5.1.1 RNA extraction from stifle and subcutaneous tissues 
Approximately 200 mg of the tissue samples (CCL, IPF and SC) collected from 
control and clinical dogs (as described in Section 2.1.1-2.1.2) were finely chopped and 
frozen in liquid nitrogen before being powdered using a mikro-dismembrator (Braun 
Biotech International, Melsungen, Germany). The dismembrator equipment was 
cooled in liquid nitrogen before use to ensure the tissue remained frozen during the 
homogenization process. Each sample was shaken at 72 x g for one minute or until 
the whole tissue become homogenised. One ml of Tri-reagent solution (Ambion, 
Applied Biosystems, Warrington, UK) was used to digest the homogenised samples 
at room temperature (20 °C) for 30 minutes before being stored at -80 °C until 
required. 
Using phenol-chloroform extraction technique, once the samples were 
required they were allowed to thaw, vortex mixed and centrifuged at 20,817 x g for 
10 minutes at 4 °C to separate insoluble material from the Tri-reagent extract. To 
every 1 ml of Tri-reagent, 200 µl of chloroform (Sigma-Aldrich, MO, USA) was added 
and the sample shaken and left at room temperature for five minutes. The sample 
was centrifuged again (20,817 x g, 15 minutes, 4 °C) with the clear, upper aqueous 
phase being carefully removed and transferred to a fresh tube. To this aqueous phase 
material, an equal volume of 70% ethanol in 0.1% diethylpyrocarbonate (DEPC)-
treated dH20 (Sigma-Aldrich) was added (Rio et al., 2010). Total RNA was then 
purified using an RNeasy mini kit® (Qiagen, Crawley, UK) according to the 
manufacturer’s instructions. Briefly, sample solution was centrifuged through an 
RNeasy column to bind the RNA to the column. Then, 10 µl of RNase-Free DNase 
(Qiagen) mixed with 70 µl of buffer RDD was added in the middle of each column for 
on-column DNase digestion which was carried out for 15 minutes at room 
temperature. The RNeasy column then was washed once with RW1 buffer (to wash 
membrane-bound RNA) and twice with RPE buffer (to remove traces of salts 
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remained on the column). The RNA was eluted using 50 µl of RNase-free water, and 
analysed using a Nanodrop 1000 spectrophotometer (Thermo Scientific, Waltham, 
USA). 
2.5.1.2 RNA extraction from cells grown in tissue culture 
CCL cells were grown in tissue culture as described previously (Section 2.4.2-
2.4.3). In brief, cells cultured at passage 2-3 in 24-well plates were lysed by the 
addition of 1 ml Tri-reagent for 1 - 2 minutes. The extract from each well was 
collected in a 1.5 ml RNase-free tube (Eppendorf, Stevenage, UK) and stored at -80° 
C until RNA extraction was performed.  
To every 1ml Tri-reagent, 200 µl of chloroform (Sigma-Aldrich, MO, USA) was 
added and the sample shaken and left at room temperature for five minutes. The 
sample was centrifuged again (20,817 x g, 15 minutes, 4 °C) and the clear, upper 
aqueous phase was carefully removed and transferred to a fresh tube. Total RNA was 
precipitated by addition of 0.5 ml of isopropanol (Sigma-Aldrich) followed by brief 
shaking and subsequent incubation at room temperature for five minutes. The 
precipitate was recovered by centrifugation (20,817 x g, 10 minutes, 4 °C) and the 
supernatant was discarded. The total RNA pellet was washed by adding 1 ml of 70% 
ethanol (Sigma-Aldrich) and following further centrifugation the supernatant was 
removed with the pellet being air dried by leaving the sample tubes open inside a 
fume hood. The extracted mRNA was dissolved in 20 µl of RNase-free water and 
measured with a Nanodrop 1000 spectrophotometer. 
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2.5.1.3 Synthesis of cDNA  
Reverse transcription was performed according to the manufacturer’s 
instructions. Briefly, 1 µg of random primers (Promega, Madison, USA) was added to 
the total RNA solution (1 µg) and heated for five minutes at 70°C. Following this 5 µl 
of 5x Reverse Transcription buffer (Promega), 2 µl of 10 mM dNTP mix (Bioline, 
London, UK), 1 µl of 200 U/µl reverse transcriptase enzyme (Promega) and RNase-
free water were added making a total volume of 25 µl. cDNA was synthesized by 
incubating the mixture at 37°C for an hour and then heated at 95°C for five minutes 
to inactivate the reverse transcriptase enzyme. cDNA samples were stored at -20 °C 
until required. 
2.5.1.4 Quantitative PCR (qPCR) 
Each cDNA sample was added to a GoTaq qPCR Mastermix containing Syber 
Green (Promega) along with sequence-specific forward and reverse primers of 
interested genes; IL-6, MCP-1, TNF-α, AGC, COL1A2, MMP-13, adiponectin, leptin, 
and visfatin (synthesised by Eurogentec, Seraing, Belgium). Primer sequences are 
shown in Table 2.1 (Clements et al., 2008). The optimal concentration for each pair 
of primers was determined by performing an assay with final concentrations of 
forward and reverse primers at 300 nM or 600 nM using Syber Green. Validation 
experiment for each set of primers and probe was performed in the thesis of Ryan 
(2008) to confirm that the amplification efficiencies were adequate. The reaction 
efficiency was 90.7%, and the correlation coefficient was 0.98. 
Samples were assayed in duplicate using a A7300 Real-Time PCR machine 
(Applied Biosystems, Warrington, UK) with the following thermal cycling parameters; 
50 °C for two minutes (for the passive reference dye measurement), denaturation at 
95°C for 10 minutes to activate Taq Polymerase (for activating the hot start Taq 
Polymerase) followed by 40 cycles of cDNA amplification (15 seconds at 95°C and 
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60°C for 1 minute). Based on previous literature, β-actin and ribosomal protein S13 
(RPS-13) were the most appropriate housekeeping genes to use in normalising gene 
expressions of interested genes using the CT values (the cycle number at which a 
defined fluorescence threshold was reached) (Tew et al., 2014, Leal et al., 2015). The 
data generated from the real time PCR were then exported to Microsoft Excel to 
analysis using 2–ΔCT method (Livak and Schmittgen, 2001). Dissociation curve analysis 
was also performed to determine that a single qPCR product was present at the end 
of the PCR reaction.  
2.5.2 Enzyme-linked immunosorbent assays (ELISA) for cytokine and 
adipokine protein measurements 
Concentrations of IL-6, TNF-α, adiponectin and leptin were determined in 
synovial fluid from both the clinical and control samples using commercially designed 
enzyme-linked immunosorbent assays (ELISA) kits. Undiluted synovial fluid was 
analysed for TNF-α (R&D Systems, Minneapolis, USA). Synovial fluid samples were 
diluted 1:3 with PBS to allow measurement of IL-6 (R&D Systems), adiponectin 
(Biovendor, Brno, Czech Republic) and leptin (Cloud-Clone Corp, Houston, USA). All 
assays were performed according to the manufacturer’s instructions, and the 
absorbance was measured with a microplate reader (Multiskan EX, Thermo Scientific, 
Vantaa, Finland) at 450 nm with the correction wavelength set at 570 nm. 
Absorbance was converted to concentration using the standard curve derived from 
serially-diluted standards (Zhang et al., 2010, Conde et al., 2011, Kathrani et al., 2012, 
Jeon et al., 2015).
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2.6 Statistical analysis 
Shapiro-Wilk test was used for testing the normality of data. The differences in dog 
breed and neutering status between controls and cases were determined by Fisher’s 
exact test. Weighted Cohen’s Kappa was used to assess observe intra- and inter-
observer agreements for radiographic scoring. The nonparametric Mann-Whitney U 
test was used to compare body fat percentage between male and female dogs. 
Kendall’s tau test was used to identify associations between age, bodyweight, BCS, 
body fat percentage and clinical presentation of dogs with CCLD. Comparisons of age, 
bodyweight, BCS and genes expression between control subjects and CCLD subjects 
were made by the non-parametric Mann-Whitney U test. Associations amongst local 
and systemic adipokines, ligament degradation biomarkers, and synovial fluid 
adipokines and inflammatory markers were assessed with Kendall’s tau test. The 
differences among in vitro experimental groups was determined using non-
parametric Friedman test, followed by the Conover post-hoc test. The difference 
between control and CCLD groups was tested with 2-way non-parametric ANOVA. 
Statistical software (StatsDirect version 3 for Windows, StatsDirect Ltd., Cheshire, UK) 
was used for the analysis, and data were considered statistically significant at P<0.05.
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Chapter 3 Association between obesity and clinical 
presentation in canine cranial cruciate ligament disease 
3.1 Introduction 
Cranial cruciate ligament disease (CCLD) is one of the most important causes 
of pelvic limb lameness in dogs (Bennett et al., 1988, Johnson et al., 1994). Evaluating 
the clinical presentation of dogs by assessing the degree of pelvic limb lameness, gait 
analysis and radiographic examination, disease severity can be determined and 
treatment plans formulated (Jerram and Walker, 2003). Lameness is visually assessed 
in veterinary practice by observing the dog at a walk and trot, then assigning a grade 
from 0 (sound) to 5 or 10 (continuous non-weight bearing) (Mathews et al., 2014). 
However, such visual gait assessment can be subjective and prone to observer bias 
(Quinn et al., 2007). Therefore, objective observations of gait analysis such as kinetic 
and kinematic evaluation are the gold standard method for determining pelvic limb 
lameness associated with CCLD (Conzemius and Evans, 2012). Force plate 
measurements such as peak vertical force (PVF), vertical impulse (VI), falling slope 
(FS), as well as asymmetry indices (AI) of these variables have been used as tools for 
objective lameness assessment (Fanchon and Grandjean, 2007, Oosterlinck et al., 
2011). In addition, since CCLD often leads to meniscal tears and the development of 
osteoarthritis (OA), radiographic examination of the stifle joints is necessary to 
determine progression of degeneration of the joints and to plan an appropriate 
treatment for dogs with CCLD (Bennett and May, 1991, Vasseur and Berry, 1992). 
Obesity is characterised by an expansion of excess white adipose tissue (WAT) 
mass that can lead to adverse health effects in humans (Cao, 2014). Obesity in dogs 
increases morbidity and mortality risk for various diseases including musculoskeletal 
disorders (Frye et al., 2016). Several techniques for measuring obesity in dogs such 
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as densitometry, dual-energy X-ray absorptiometry (DEXA), electrical impedance and 
morphometric methods have previously been described (German, 2006). Evaluating 
body condition scores (BCS), based on visual assessment and palpation, is most 
commonly used by veterinarians as it is inexpensive, convenient and non-invasive 
(Burkholder, 2000). Nonetheless, the assessment of BCS is subjective (German, 
2006); therefore, DEXA is used as the gold standard for measuring body fat in many 
studies (Larsson et al., 2014, German et al., 2015). 
Increased adiposity is a risk factor for lower limb injury in humans including 
unilateral anterior cruciate ligament (ACL) disease (Mattila et al., 2007, Takata et al., 
2007). Studies have also highlighted the association between increase bodyweight 
and the development of canine CCLD (Whitehair et al., 1993, Witsberger et al., 2008). 
Compared with dogs in ideal bodyweight, obese dogs have 3.76 times the risk of 
developing CCLD (Adams et al., 2011). However, it remains unclear whether this 
increased risk is due to the increased bodyweight of dogs alone or also related to the 
effects of having excessive amounts of adipose tissue. Therefore, the main objective 
of this part of the study was to study the effects of both mechanical and humoral 
factors in dogs with CCLD with varying amounts of adipose tissue.  
3.1.1 Aims 
 To observe the association between both mechanical factor of obesity 
(bodyweight) and body condition score (BCS) with the clinical presentation 
(lameness score, gait variables from force plate measurements, radiographic 
examination score) in dogs with CCLD.
  
 
 
   
  
65 
3.2 Methods 
3.2.1 Patient selection and signalment 
Dogs referred for surgical treatment of CCLD at Small Animal Teaching 
Hospital, University of Liverpool were recruited to the study from April 2014 to 
December 2015. Dogs were included in the study if they had a diagnosis unilateral 
CCLD as determined by presence of the cranial drawer sign, and were excluded if they 
had bilateral disease or obvious pain upon orthopaedic examination in other joints. 
Informed owner consent was obtained, according to local institutional ethical 
requirements (VREC192, see Section 2.1.2 in Chapter 2). Animal signalment including 
dog breed, sex, age and bodyweight were recorded as described previously (Chapter 
2 Section 2.1.2).  
3.2.2 Assessment of obesity and adiposity in dogs with CCLD 
Measurements for determining obesity in the recruited animals were 
obtained as described in Chapter 2 (Sections 2.2 and 2.3.4). In brief, we used a nine-
point scale BCS system to determine body composition of dogs (see Chapter 2 Section 
2.2, Appendix 1). In addition, a DEXA scan was performed to precisely define the 
percentage of body fat mass (Chapter 2 Section 2.3.4). 
3.2.3 Assessment of the clinical presentation of dogs with CCLD 
The clinical presentation of CCLD dogs was assessed by determining lameness 
scores, force plate measurements and radiographic examination scores (Chapter 2 
Section 2.3.1 – 2.3.3). 
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3.2.3.1 Lameness score 
Lameness of CCLD dogs was visually evaluated during walking by an ECVS 
resident or RCVS or ECVS Diploma holding orthopaedic surgeon, and scored on a scale 
of 0 – 10, as no detectable lameness (grade 0), and most severe lameness (grade 10) 
as described in Chapter 2 Section 2.3.1.  
3.2.3.2 Kinetic gait analysis using force plate measurements 
Kinetic gait analysis using force plate measurements were performed at walk 
(velocity 1.0–1.3 m/s) prior to surgical treatment for CCLD. Data including peak 
vertical force (PVF), vertical impulse (VI), falling slope (FS) and asymmetry indices (AI) 
of these variables (AI PVF, AI VI, AI FS) of the affected limbs with at least 5 replicates 
were collected and analysed (see Chapter 2 Section 2.3.2).  
3.2.3.3 Radiographic examination and scoring 
Paired sets of anonymised radiographs (mediolateral and caudocranial 
projections) of the affected stifle joints (see Appendix 2) were scored by two 
investigators: WS (an MVM) and EC (a board-certified diplomate in veterinary surgery 
[DipECVS]). Each observer scored the radiographic images of each affected stifle joint 
independently twice (at least 2 weeks apart) for evidence of osteophytosis based on 
a 5-point Likert scale, with no osteophytosis (score 0), mild osteophytosis (score 1), 
moderate osteophytosis (score 2), marked osteophytosis (score 3), and severe 
osteophytosis (score 4) (Innes et al., 2004) (see Chapter 2 Section 2.3.3) . 
3.2.4 Statistical analysis 
Data were expressed as mean ± standard deviation (SD), median and range, 
unless where indicated. Weighted Cohen’s Kappa was used to assess observe intra- 
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and inter-observer agreements for radiographic scores (described in Section 3.2.3.3); 
results between 0.01 and 0.20 were classed as slight agreement, those between 0.21 
and 0.40 were classed as fair agreement, those between 0.41 and 0.60 were classed 
as moderate agreement, those between 0.61 and 0.80 were classed as substantial 
agreement, and those between 0.81 and 0.99 were classed as almost perfect 
agreement (Landis and Koch, 1977). The mean radiographic score from both 
observers was used in the final statistical analysis. 
The nonparametric Mann-Whitney U test was used to compare body fat 
percentage derived from DEXA (Section 3.2.2) between male and female dogs. Since 
the data were not normally distributed, as determined by a Shapiro-Wilk test. 
Kendall’s tau test was used to compare associations between body fat percentage 
and age, bodyweight and BCS. Finally, Kendall’s tau was also used to determine the 
association of age, bodyweight and body fat with the clinical presentation of dogs 
with CCLD (Section 3.2.3). All data were analysed using statistical software 
(StatsDirect version 3 for Windows; StatsDirect Ltd., Cheshire, UK). Data were 
considered statistically significant at P < 0.05.
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3.3 Results 
3.3.1 Signalment and clinical presentation of dogs with CCLD 
Thirty dogs with CCLD met the inclusion criteria for the study. Several breeds 
of dog were represented including mixed breed (3), Siberian Huskies (3), 
Staffordshire Bull Terriers (3), Border Collies (2), Golden Retrievers (2), Labrador 
Retrievers (2), Rottweilers (2), West Highland White Terriers (2), American Bulldog 
(1), Beagle (1), Border Terrier (1), Boxer (1), Bullmastiff (1), Cocker Spaniel (1), English 
Springer Spaniel (1), Flat Coated Retriever (1), German Shepherd dog (1), 
Labradoodle (1) and St Bernard (1).  
There were entire female (3), neutered female (11), entire male (1) and 
neutered males (15) dogs recruited in this study. Median age was 62 months (range 
18-126 months), whilst median bodyweight was 29.4 kg (range 9.8 – 64.1 kg).  
3.3.1.1 Body condition score and body fat percentage 
Median BCS and body fat percentage of dogs recruited in this study were 
score 6 out of 9 (range 3 – 8) and 35.0% (range 7.7 – 51.7%) respectively (Table 3.1). 
 
Table 3.1 Body condition score and body fat of dogs with CCLD. 
Body composition Mean ± SD Median Range 
Body condition score (0/9-9/9) 5.7 ± 1.2 6 3 - 8 
Body fat (%) 32.0 ± 12.4 35.0 7.7 - 51.7 
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3.3.1.2 Lameness score and kinetic gait analysis  
Median lameness score was 5/10 (range 2/10 – 10/10); the results for kinetic 
gait analysis parameters from the force platform are presented in Table 3.2. 
 
 
Table 3. 2 Values obtained from the measurement of lameness in dogs with CCLD 
using both subjective lameness scores and objective kinetic gait analysis. 
Gait variable Mean ± SD Median Range 
Lameness score 5.8 ± 2.9 5 2 - 10 
Gait parameters    
PVF (%BW) 36.2 ± 14.4 34.1 17.4 – 67.8 
VI (%BW) 7.2 ± 3.0 6.7 2.0 – 15.9 
FS (%BW/msecs) -0.2 ± 0.2 -0.2 -0.6 – -0.1 
AI PVF (%) 52.6 ± 33.8 51.1 2.1 – 134.5 
AI VI (%) 54.4 ± 39.5 48.2 1.9 – 129.9 
AI FS (%) 40.2 ± 38.4 29.2 0.6 – 166.7 
PVF:  peak vertical force; VI:  vertical impulse; FS:  falling slope; AI:  asymmetry index; BW: 
bodyweight; msecs: milliseconds 
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3.3.1.3 Radiographic scoring 
The median radiographic score of affected stifle joints following two blinded 
measurements by two investigators for CCLD dogs was 1 out of 4 (range 0/4 - 3/4). 
The intra-observer agreements from each investigator were substantial (Kappa 0.69 
and 0.79 for WS and EC respectively, Table 3.4), but only fair agreement was obtained 
for inter-observer agreement (Kappa 0.28, Table 3.3). 
Table 3. 3 Intra-  and inter- observer agreements following blinded radiographic 
assessment of affected canine stifle joints. 
 Intra-observer agreement  Inter-observer agreement 
 WS EC  WS and EC 
Kappa 0.69 0.79  0.28 
95 %CI 0.53 -0.85 0.62 - 0.96  0.12 - 0.45 
P < 0.001 < 0.001  0.002 
WS:  Wipawee Saengsoi; EC: Eithne Comerford; CI:  confidence interval 
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3.3.2 Associations between body fat composition and animal 
signalment 
Figures 3.1 represents the scatter plots along with regression trend of 
associations between body fat percentage and animal signalment. There were no 
differences in body fat percentage between male and female dogs with CCLD (P = 
0.984, Figure 3.1A). However, body fat percentage was positively associated with age 
(Kendall’s tau = 0.30, P = 0.019; Figure 3.1B), bodyweight (Kendall’s tau = 0.28, P = 
0.029; Figure 3.1C) and BCS (Kendall’s tau = 0.62, P < 0.001; Figure 3.1D). 
3.3.3 Relationship between all parameters related to obesity and the 
clinical presentation of dogs with CCLD 
The association between factors-related to obesity, as observed in Section 
3.3.2 (age, bodyweight and body fat), and clinical presentation of CCLD dogs 
(lameness score, radiographic score, force platform data) were determined. A weak 
negative correlation was found between bodyweight and PVF (Kendall’s tau = -0.31, 
P = 0.016), whereas a positive correlation between bodyweight and FS was found 
(Kendall’s tau = 0.36, P = 0.006, Table 3.4). However, no associations were found 
between age and body fat composition with any other clinical parameters (Table 3.4)
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Figure 3. 1  Graphical presentation of the associations between percentage body fat mass 
and animal signalment. 
Scatter plots and regression trend of comparison between body fat percentage with sex ( A) , age 
(B), bodyweight (C) and body condition score (D) in dogs with CCLD. kg: kilogram. The scatter plots 
show no difference of body fat percentage between male and female dogs, the horizontal lines 
represent mean (A) .  Whilst there were positive correlations between body fat percentage with 
age (B), bodyweight (C) and body condition score (D) of dogs.  
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Table 3.4 Relationship of all parameters used to determine obesity and the clinical presentation of dogs with CCLD. 
  Lameness score PVF VI FS AIPVF AIVI AIFS Radiographic score 
Age Kendal 0.13 0.12 0.16 -0.03 -0.11 -0.15 0.08 0.09 
 P 0.352 0.353 0.211 0.830 0.412 0.253 0.544 0.554 
Bodyweight Kendal 0.03 -0.31* 0.09 0.36* 0.06 -0.01 -0.13 0.06 
 P 0.832 0.016 0.464 0.006 0.630 0.929 0.309 0.684 
Body fat %  Kendal 0.06 -0.11 -0.12 0.06 0.01 0.11 -0.06 0.22 
 P 0.688 0.392 0.353 0.643 0.915 0.392 0.643 0.137 
PVF: peak vertical force; VI: vertical impulse; FS: falling slope; AI: asymmetry index (*P < 0.05) 
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3.4 Discussion 
Increased body fat mass has been found in humans with chronic unilateral 
ACL disease (Takata et al., 2007). Bodyweight and body mass index (BMI) are also risk 
factors for non-contact ACL injury in women (Uhorchak et al., 2003). In dogs, obesity 
increases the risk of CCLD by 4 times (Adams et al., 2011). Therefore, the hypothesis 
for this study was that both mechanical and humoral factors of obesity could be 
involved in pathophysiology of CCLD. Specifically, this study aimed to investigate the 
link between obesity and the clinical presentation of canine CCLD to elucidate any 
significant associations, which could be used in the future management of this 
condition. 
3.4.1 Signalment, bodyweight, and body fat mass 
Intrinsic factors of dogs such as breed, sex, neuter status, age and bodyweight 
have been identified as possible risk factors for CCLD (Whitehair et al., 1993, 
Witsberger et al., 2008). Although CCL injury can be seen in all breeds of dog (Jerram 
and Walker, 2003), it occurs more commonly in those from large breeds (Witsberger 
et al., 2008). Almost half of dogs recruited in this study were large- or giant-dog 
breeds; however, some small and medium dog breeds were also included. The 
number of male and female dogs represented was approximately the same. No sex 
differences for CCLD have been reported (Duval et al., 1999, Witsberger et al., 2008), 
besides one recent study which reported twice the risk of CCLD in female dogs as 
compare to the males (Adams et al., 2011). A further finding of this study was that 
the majority of dogs were neutered. In a similar manner, previous studies have 
demonstrated that neutered male and female dogs are 1.68 - 2.35 times more likely 
to have CCLD than entire dogs (Witsberger et al., 2008). However, it has been 
suggested that owners of neutered dogs are more likely to bring their dogs to 
veterinarians than owners of sexually intact dogs (Witsberger et al., 2008). In the 
current study, median age of dogs with CCLD was five years, a finding that is 
consistent with previous work showing dogs older than 4 years old and large to giant 
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breeds are reportedly predisposed to CCLD (Whitehair et al., 1993). We observed a 
median bodyweight of 29.4 kg in dogs with CCLD in our cohort. In addition, most dogs 
in our study were considered overweight with a BCS of at least 6 out of 9.   
To the best of our knowledge, this is the first study that has attempted to 
determine the relationship between body fat percentage (determined by DEXA) and 
canine CCLD. DEXA was used because it is known to be precise and accurate (German 
et al., 2010a). Indeed, a statistically significant association between BCS and body fat 
percentage was identified, whilst a moderate correlation between bodyweight and 
body fat percentage was also seen. In addition to these findings, a positive correlation 
between dog age and body fat percentage was noted. In a similar manner, a previous 
study has documented that as the age of dogs increases, so too does the risk of being 
overweight, as measured by BCS (Colliard et al., 2006). 
3.4.2 Relationship of obesity and the clinical presentation of dogs with 
CCLD 
3.4.2.1 Visual lameness 
Pelvic limb lameness is commonly seen in dogs with CCLD where the severity 
can be varied (Jerram and Walker, 2003). A previous human study has demonstrated 
that the risk of osteoarthritis (OA) can be related to both adipose mass and central 
adiposity (Wang et al., 2009), whilst reducing body fat is more important than 
reducing in bodyweight for symptomatic relief of knee OA in humans (Toda et al., 
1998). However, no statistically significant correlations were noted between 
bodyweight or body fat percentage with visual lameness of the affected dogs in this 
study. It is generally known that lameness evaluation can be challenging in dogs, and 
there is evidence of low inter-rater agreement when visually judging lameness 
(Waxman et al., 2008).  
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3.4.2.2 Force plate-detected lameness 
It has been reported that subjective scoring scales poorly agree with objective 
lameness assessments such as force plate measurement (Quinn et al., 2007). Kinetic 
gait analysis using a force platform represents the gold standard method of 
objectively assessing lameness in dogs (Conzemius and Evans, 2012). Associations 
were identified between bodyweight and certain gait variables measured with force 
plate (PVF and FS) in this study. The PVF is the most accurate measurement for kinetic 
lameness evaluation and usually correlates with vertical impulse (Fanchon and 
Grandjean, 2007). In dogs with CCLD, PVF of the affected limb is usually reduced 
(Conzemius et al., 2005, Fischer et al., 2013). The negative correlation between 
bodyweight and PVF found in our study might imply that dogs with greater 
bodyweight are less willing to weight bear on the lame limb during the gait cycle. 
Therefore, a low magnitude of ground reaction force was observed (Fischer et al., 
2013). The FS value indicates the time for a dog to unload its limb once maximum 
force has been reached; the negative results seen in dogs with CCLD, compared with 
control dogs, suggest more rapid unloading possibly as a the result of pain (Evans et 
al., 2005). Negative FS results have been observed when dogs with hip OA are treated 
with placebo comparing to non-steroidal anti-inflammatory drugs (Malek et al., 
2012). However, the author of that study interpreted the changes in FS value 
detected in placebo-treated dogs as an undesirable effect. The positive correlation 
between bodyweight and FS observed in this study indicated that heavier dogs took 
a longer time to unload their injured limb. Likewise, previous studies in obese 
children have shown that the duration of the gait cycle is longer in obese subjects 
than normal-weight subjects at both slow and fast walking speeds. It was speculated 
in this study that they spend more time in stance phase and double support phase in 
which bodyweight is supported by both legs (Hills and Parker, 1992, McGraw et al., 
2000). This might suggest a possible link between movement inefficiency in the gait 
cycle of dogs with a bigger bodyweight. 
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3.4.2.3 Radiographic score 
Canine CCLD is a leading cause of stifle OA (Vasseur and Berry, 1992) and 
radiographs are routinely performed to detect progression of OA occurring in 
affected stifles (Jerram and Walker, 2003). Osteophytes can occur at the margins of 
the femoral trochlea as early as three days after CCLD using Pond Nuki model 
(Gilbertson, 1975). Osteophyte score is correlated with OA progression secondary to 
CCLD (Innes and Barr, 1998). Therefore, a grading system of radiographic OA, based 
on osteophyte formation in canine stifles joints has been developed and validated 
(Innes et al., 2004). The scoring system used in this study showed substantial intra-
observer agreement as was previously reported (Innes et al., 2004). However, the 
inter-observer agreement was fair (0.28). This result may well have been the result 
of differences in experiences between two observers. Although evaluating 
osteophytes as part of a scoring system is convenient and give a good intra-observer 
agreement, there are also other scoring systems that might be more sensitive for 
screening OA progression (Vasseur and Berry, 1992, Au et al., 2010).  
In previous research, more osteophyte formation is known to occur in larger 
and more obese dogs, although no significant correlation between bodyweight and 
osteophyte formation was found in those studies (Heffron and Campbell, 1979, 
Rayward et al., 2004). Our study observed that different grades of radiographic OA 
occurred in the affected stifle joints; however, there were no statistically significant 
associations of radiographic score with body fat percentage, bodyweight or age of 
dogs. 
3.4.3 Effect of mechanical factors of obesity on CCL 
Previous studies on cyclic mechanical stretching of tendon fibroblasts suggest 
that increased inflammatory mediator production can lead to tendinitis (Wang et al., 
2003), a phenomenon that might also occur in ligament cells. Furthermore, a 
  
 
 
   
  
78 
histological study has demonstrated alterations of the cellular and extracellular 
matrix in torn CCL, which have resulted from the cumulative effects of remodelling 
and adaptation to mechanical loading (Hayashi et al., 2003). These findings support 
the theory that obesity can contribute to the incidence of CCLD in large size and heavy 
weight dogs, as higher loads would be placed on the stifles (Griffon, 2010). The 
mechanism could involve accumulative effect of repetitive loading resulting in 
accelerating degenerative processes, as well as weakening of the ligament and 
surrounding soft tissue fatigue which can could contribute to ligament inflammation 
and degeneration (Johnson and Johnson, 1993, Moore and Read, 1996a). 
The most notable limitation of this study was the fact that it was small yet 
there was a large variety of dog breeds, sizes, and degrees of body fat. Given such 
variability, the study was likely to be somewhat underpowered therefore reducing 
obesity factors such as studying differences between breeds, a limited range of 
bodyweights and age, as well as recruiting more subjects should be considered in 
future investigations.
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3.5 Conclusion 
This study investigated the effect of obesity, in terms of bodyweight and body 
fat percentage, on clinical presentation of dogs with CCLD, including lameness scores, 
gait parameters from force plate analysis and radiographic scores. Some association 
was seen between bodyweight and the clinical manifestation of CCLD, in terms of the 
severity of lameness as detected by force plate. In contrast, there was no significant 
association with body fat mass. Further studies are required to determine the basis 
for the association between bodyweight and CCLD severity. 
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Chapter 4 Adipokines as metabolic mediators in canine 
cranial cruciate ligament disease 
4.1 Introduction 
Cranial cruciate ligament disease (CCLD) in dogs is a degenerative condition 
with a complex aetiopathogenesis involving inflammatory stifle arthritis, collagen 
degradation (Muir et al., 2005, Doom et al., 2008) and many predisposing factors 
including obesity (Taylor-Brown et al., 2015). White adipose tissue has many 
functions and is now considered to be an endocrine organ producing a variety of 
hormones, termed adipokines. The most well-studied adipokines include leptin, 
adiponectin, and visfatin (Lagowska and Jeszka, 2011). Other adipokines include 
cytokines and chemokines (sometimes referred to as adipocytokines) and these 
include interleukin-6 (IL-6), macrophage chemotactic protein-1 (MCP-1) and tumour 
necrosis factor-α (TNF-α) (Fain et al., 2004). Dysregulation of these adipokines can 
have local or systemic effects on inflammatory responses, which contribute to many 
obesity-associated disorders (Cao, 2014). In this respect, associations have been 
demonstrated between obesity-related metabolic factors and musculoskeletal 
disorders such as osteoarthritis (OA) (Grotle et al., 2008, Griffin et al., 2010). There is 
also in vitro evidence that adipokines, such as leptin and visfatin, can disrupt cartilage 
homeostasis and induce pro-inflammatory mediators such as IL-6 and IL-8 (Wang et 
al., 2015). 
The infrapatellar fat pad (IPFP) is an active adipose tissue located in the knee 
joint and known to secrete various adipokines into the joint (Ioan-Facsinay and 
Kloppenburg, 2013). Previous studies have indicated a crosstalk between IPFP and 
other joint tissues such as cartilage and chondrocytes, which implies that this 
crosstalk might contribute to the pathogenesis of OA (Bastiaansen-Jenniskens et al., 
2012, Bastiaansen-Jenniskens et al., 2013, Chen et al., 2016). In contrast, medium 
conditioned by OA IPFP have been found to have inhibitory catabolic effect on 
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articular cartilage (Bastiaansen-Jenniskens et al., 2012, Bastiaansen-Jenniskens et al., 
2013, Chen et al., 2016). 
Despite such research, the mechanisms by which obesity predisposes to OA 
remain unclear, not least whether there is an association between the systemic or 
local release of adipokines (Kwon and Pessin, 2013). Furthermore, there have been 
no studies assessing the association between obesity and CCLD. Therefore, our 
hypothesis is that chemical mediators secreted from either systemic or local (intra-
articular stifle joint) adipose tissues may influence on CCLD pathophysiology and 
clinical presentation of dogs with CCLD. 
4.1.1 Aims 
 To examine differences in gene expression of pro-inflammatory cytokines, tissue 
degradation biomarkers, and adipokine expression in dogs with and without 
CCLD. 
 To determine the association between both local and systemic adipokines, pro-
inflammatory cytokines and tissue degradation biomarkers in CCL tissues and 
synovial fluid of dogs with CCLD. 
 To investigate the relationship between chemical mediators in the stifle joint and 
the clinical presentation of dogs with CCLD. 
 To examine the relationship of body fat composition and chemical mediators 
from both local and systemic adipose tissues of dogs with CCLD. 
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4.2 Methods 
4.2.1 Animals and sample collection 
Control group: Dog cadavers euthanased for reasons other than 
musculoskeletal disease were used as controls. Tissues including CCL and IPFP were 
collected from the right stifle joint and subcutaneous (SC) fat were collected from the 
right inguinal area of the cadavers (Chapter 2 Section 2.1.1). 
Clinical group: Client-owned dogs referred for surgical treatment of CCLD 
were recruited. Dogs were included in the study if they had a diagnosis of unilateral 
CCLD as determined by presence of the cranial drawer sign and were excluded if they 
had bilateral disease or obvious pain upon orthopaedic examination in other joints. 
Ruptured CCL, IPFP tissues and synovial fluid were collected from the affected joint. 
SC tissues were obtained from the surgical site (Chapter 2 Section 2.1.2). 
Animal signalment including breed, sex, neuter status, age, bodyweight and 
body condition score (see Appendix 1) of all dogs were measured and recorded. 
Ethical permission for using the control and clinical material was approved by the 
Veterinary Research Ethics Committee, School of Veterinary Science (VREC213 and 
VREC192) and signed owner consent was obtained for the clinical group (Chapter 2 
Section 2.1). 
4.2.2 Measurement of pro-inflammatory cytokines, tissue degradation 
biomarkers and adipokines gene expression in dogs with and without 
CCLD 
Gene expression of pro-inflammatory cytokines, tissue degradation 
biomarkers and adipokines was measured in tissue samples as described in Chapter 
2 Section 2.5. Briefly, RNA was extracted from ground tissues using guanidinium 
thiocyanate-phenol-chloroform extraction technique and was purified using RNeasy 
mini kit®. Reverse transcription was performed to synthesise cDNA, which was used 
in quantitative PCR (qPCR) assays. The assays were to determine expression for a 
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range of genes depending on the tissue type. IL-6, TNF-α, MCP-1, aggrecan (AGC), 
collagen-1 (COL-1) and matrix metalloproteinase (MMP)-13 were measured in CCLs. 
Adiponectin, leptin, visfatin, IL-6, TNF-α, MCP-1 and MMP-13 were measured in IPFP 
and SC. 
4.2.3 Measurement of adipokines and pro-inflammatory cytokines in 
synovial fluid 
Synovial fluid was obtained from dogs with CCLD for measurement of 
adipokine (adiponectin, leptin) and pro-inflammatory cytokine (IL-6, TNF-α) 
concentrations using ELISA commercial kits (TNF-α (R&D Systems); IL-6 (R&D 
Systems), adiponectin (Biovendor); leptin (Cloud-Clone Corp)). Briefly, 100 µl of 
diluted or undiluted synovial fluid were added to pre-coated wells in duplicate. All 
assays were performed according to the manufacturers’ instructions and the 
absorbance was measured with a microplate reader at 450 nm with the correction 
wavelength set at 570 nm. Protein concentrations were calculated using the standard 
curve derived from the results of a set of serially-diluted standards (Chapter 2 Section 
2.5.2). 
4.2.4 Clinical presentation of dogs with CCLD 
The clinical presentation of dogs with CCLD was assessed by lameness score, 
force plate measurement data including peak vertical force (PVF), vertical impulse 
(VI), falling slope (FS), together with asymmetry indices of these values and 
radiographic score. 
4.2.4.1 Lameness score 
Lameness of CCLD dogs was visual evaluated during walking, and scored on a 
Likert scale of 0 – 10, as no detectable lameness (grade 0), and most severe lameness 
(grade 10) (Chapter 2 Section 2.3.1). 
 
 84 
  
4.2.4.2 Force plate measurement 
Gait analysis using force plate measurement was performed at the walk 
(velocity 1–1.3m/s). Data including PVF, VI, FS and AI of these variables (AI PVF, AI VI, 
AI FS) were collected (Chapter 2 Section 2.3.2).  
4.2.4.3 Radiographic score 
Thirty paired sets of stifle radiographs (mediolateral and caudocranial 
projections) of the affected joints were scored twice by two blinded investigators: 
WS (DVM) and EC (DipECVS). Radiographic scores were assessed by the evidence of 
osteophytosis (see Appendix 2) based on a 5-point Likert scale, with no osteophytosis 
(score 0), mild (score 1), moderate (score 2), marked (score 3), and severe (score 4) 
(Innes et al., 2004). The average values from four rounds of scoring were used in data 
analysis (Chapter 2 Section 2.3.3). 
4.2.5 Measurement of body composition 
As part of the clinical investigations performed in dogs with CCLD prior to 
surgical management of this condition, the body fat composition was measured using 
fan-beam dual-energy X-ray absorptiometry (DEXA, Lunar Prodigy Advance; GE 
Lunar), and then analysed using enCORE 2004 software (v8.70.005, GE Lunar) 
(Chapter 2 Section 2.3.4). 
4.2.6 Statistical analysis 
Statistical software (StatsDirect version 3 for Windows, StatsDirect Ltd., 
Cheshire, UK) was used for statistical analysis. Data were expressed as median and 
range, unless indicated. The differences in dog breed and neutering status between 
controls and cases were determined by Fisher’s exact test. Since the samples were 
not normally distributed, comparisons of age, bodyweight, BCS and genes expression 
between control subjects and CCLD subjects were made by the non-parametric 
Mann-Whitney U test. Associations amongst local and systemic adipokine profiles, 
ligament degradation biomarkers, and synovial fluid adipokines and inflammatory 
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markers were assessed with Kendall’s tau test. A P value <0.05 was considered to be 
statistically significant. 
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4.3 Results 
4.3.1 Baseline data of animal signalment 
The control group comprised 26 dogs, from several breeds including 
Staffordshire Bull Terrier (20), mixed breed (3), Rottweiler (2), and Jack Russell Terrier 
(1). Seven of the dogs were entire female, 17 of the dogs were entire male and the 
remaining 2 were neutered male. There were 28 dogs in the CCLD group and the 
breeds included: mixed breed (3), Siberian Husky (3), Border Collie (2), Golden 
Retriever (2), Labrador Retriever (2), Rottweiler (2), Staffordshire Bull Terrier (2), 
West Highland White Terrier (2), American Bulldog (1), Beagle (1), Boxer (1), 
Bullmastiff (1), Cocker Spaniel (1), English Springer Spaniel (1), Flat Coated Retriever 
(1), German Shepherd Dog (1), Labradoodle (1), and St Bernard (1). There were entire 
female dogs (2), neutered female (10), entire male (1) and neutered male (15).   
Dogs from retriever breeds (P = 0.024) and neutered dogs (P <0.001) were 
over-represented in the CCLD group compared with the control group (Table 4.1). 
Conversely, there were no differences in the disease occurrence between male and 
female dogs (P = 0.264, Table 4.1). In addition, age, bodyweight, and body condition 
score were all significantly greater in the dogs with CCLD than in the controls (P = 
0.002, P = 0.004, and P < 0.001 respectively, Table 4.1). Median body fat was 35% 
(range 8 - 52%) in the CCLD dogs, but not measured in the control group given the 
fact that they were cadavers. 
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Table 4.1 Comparing baseline data of control and dogs with CCLD. 
Category Control (n=26)  Case (n=28)    P value 
 Mean±SD Median Range  Mean±SD Median Range  
Being Retriever breed (n) n = 0 
n = 19 
n = 2 
 n = 6 0.024 
Being male (n)  n = 16 0.264 
Being neutered (n)  n = 25 <0.001 
Age (mt) 40.2±17.0 36 24 - 96  63.7±29.9 62 18 - 126 0.002 
Body weight (kg) 22.1±5.9 22.8 11 - 35  30.9±13.6 29.1 10.4 – 64.1 0.004 
Body condition score (0/9-
9/9) 
4.2±1.0 4 2 - 6  5.6±1.2 6 3 - 8 <0.001 
n: number of dogs; mt: month; kg: kilogram 
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4.3.2 Gene expression of chemical mediators in CCL and adipose tissue 
of control dogs and dogs with CCLD 
Gene expression of pro-inflammatory cytokines (IL-6, MCP-1, TNF-α) and tissue 
degradation biomarkers (AGC, COL-1, MMP-13) were significantly greater in the CCL 
of dogs with CCLD compared to those in the controls (P = 0.006 for MCP-1 and 
P<0.001 for the other genes, Figure 4.1A). In contrast, within the IPFP, gene 
expression of both adiponectin and leptin were significantly greater in the control 
group (P = 0.001 and P = 0.029 respectively), but no difference in visfatin gene 
expression was found (P = 0.099, Figure 4.1B). Gene expression of IL-6 in IPFP derived 
from CCLD dogs was significantly greater (P = 0.006), whereas gene expression of 
MMP-13 was markedly lower than the control group (P = 0.007, Figure 4.1B). 
However, no difference in the gene expression of MCP-1 and TNF-α was found 
between these two groups, with P values of 0.654 and 0.539 respectively (Figure 
4.1B). Finally, in SC adipose tissue, gene expression of leptin (P < 0.001), IL-6 (P = 
0.048), MCP-1 (P = 0.001), TNF-α (P = 0.001) and MMP-13 (P = 0.009) were greater in 
dogs with CCLD than in control dogs (Figure 4.1C). 
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Figure 4 .1  Comparing genes expression of chemical biomarkers in CCLs and adipose tissues between control dogs and dogs with CCLD. 
The differences in genes expression of adipokines and chemical biomarkers in cranial cruciate ligaments (A), infrapatellar fat (B) and subcutaneous fat (C) are shown 
between controls and cases . Boxes contain values from 1st to 3rd quartile, lines inside boxes indicate median values and endpoints of vertical lines represent 
maximum and minimum (*P < 0.05, **P < 0.01). IL-6: interleukin-6; MCP-1: macrophage chemotactic protein-1; TNF-α: tumour necrosis factor-α; AGC: aggrecan, COL-
1: type I collagen; MMP-13: matrix metalloproteinase-13. Figures show all adipokines and chemical biomarkers were significantly increased in CCLs of dogs with 
CCLD (A). Adiponectin, leptin and MMP- 13 were significantly decreased, whereas IL- 6 was significantly increased in infrapatellar fat of the CCLD group (B). There 
was a significant increase in leptin and all chemical biomarkers in subcutaneous fat of the CCLD group (C). 
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4.3.3 The association of local and systemic adipokines with CCLD 
biomarkers in synovial fluid and CCL tissues 
Protein level of adipokines and pro-inflammatory cytokines in synovial fluid 
of dogs with CCLD measured by ELISA are shown in Table 4.2. Focusing on two sources 
of adipose-derived adipokines of dogs with CCLD, there were some associations 
between adipokines in IPFP and SC and the disease markers in synovial fluid and CCL 
tissues. In IPFP, adiponectin and visfatin gene expression were positively correlated 
with both TNF-α concentration in synovial fluid (P = 0.045) and its gene expression in 
CCL (P = 0.033), whilst leptin was inversely association with MMP-13 in CCLs (P = 
0.042, Table 4.3). Conversely, although the expression of visfatin in SC adipose tissue 
was positively correlated with TNF-α concentration in synovial fluid, it was negatively 
correlated with TNF-α gene expression in CCL tissues (P = 0.045 and P = 0.046 
respectively, Table 4.3). 
 
 
 
Table 4. 2 Protein level of adipokines and pro- inflammatory cytokines in synovial fluid of 
dogs with CCLD. 
 Mean±SD Median Range 
Adiponectin (ng/ml) 57.2±23.2 49.0 35.9 - 114.7 
Leptin (ng/ml) 16.9±16.5 8.9 2.1 - 52.2 
IL-6 (pg/ml) 614.7±542.3 450.6 29.5 - 1,848.6 
TNF-α (ng/ml) 4.0±6.3 0.9 0.9 – 18.9 
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Table 4. 3 Association between gene expression level of local and systemic adipokines with protein 
level of pro- inflammatory cytokines in synovial fluid and gene expression level of tissue degradation 
biomarkers in cranial cruciate ligaments. 
 Adipokines 
  Synovial fluid  Cranial cruciate ligament 
  IL-6 TNF-α   IL-6 MCP-1 TNF-α AGC COL-1 MMP-13 
Infrapatellar fat          
Adiponectin Kendal 0.08 0.49*  -0.02 0.03 0.06 0.15 0.33 -0.16 
 P 0.731 0.045  0.928 0.869 0.742 0.384 0.053 0.365 
Leptin Kendal 0.00 0.34  0.03 -0.02 -0.01 0.15 0.30 -0.39* 
 P 1.000 0.193  0.870 0.928 0.961 0.418 0.105 0.042 
Visfatin Kendal 0.19 -0.25  0.23 0.17 0.32* 0.03 -0.10 -0.03 
 P 0.340 0.266  0.151 0.278 0.033 0.849 0.505 0.830 
           
Subcutaneous fat          
Adiponectin Kendal 0.04 -0.39  0.29 0.03 -0.02 0.19 0.04 0.06 
 P 0.857 0.133  0.088 0.861 0.897 0.227 0.809 0.697 
Leptin Kendal -0.06 -0.25  0.25 0.02 -0.08 0.14 -0.09 0.12 
 P 0.835 0.365  0.177 0.934 0.622 0.421 0.600 0.472 
Visfatin Kendal 0.33 0.55*  0.03 -0.01 -0.33* -0.18 0.24 -0.15 
  P 0.211 0.045  0.869 0.970 0.046 0.270 0.136 0.382 
IL-6: interleukin-6; TNF-α: Tumour necrosis factor-α; MCP-1: macrophage chemotactic protein-1;  
AGC: aggrecan; COL-1: type 1 collagen; MMP-13: matrix metalloproteinase-13 (*P <0.05). 
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4.3.4 The association between chemical mediators in the stifle joint and the 
clinical presentation in dogs with CCLD 
There was an association between leptin concentration in synovial fluid and lameness 
of dogs with CCLD. Leptin was positively correlated with lameness score (visual gait 
assessment, P = 0.032), whilst leptin was negatively correlated with PVF from the force plate 
measurement (P = 0.015, Table 4.4). However, there was no association between chemical 
mediators expressed in CCL tissues and the clinical presentation of lame dogs (Table 4.4). 
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Table 4.4 Association between protein level of pro-inflammatory cytokines in synovial fluid, gene expression level of tissue degradation biomarkers 
in cranial cruciate ligaments and clinical presentation of dogs with CCLD. 
  Lameness score PVF VI FS AI PVF AI VI AI FS Radiographic score 
Synovial fluid 
Adiponectin Kendal -0.22 0.20 -0.12 -0.24 0.18 0.22 0.12 -0.28 
 P 0.290 0.299 0.520 0.216 0.347 0.255 0.520 0.182 
Leptin Kendal 0.52* -0.51* -0.23 0.23 0.10 0.26 0.03 0.13 
 P 0.032 0.015 0.272 0.272 0.625 0.222 0.903 0.573 
IL-6 Kendal -0.15 -0.16 -0.16 0.02 0.10 0.25 -0.12 -0.36 
 P 0.492 0.426 0.426 0.921 0.619 0.196 0.551 0.099 
TNF-α Kendal -0.15 0.09 0.12 0.00 0.00 0.03 0.00 -0.24 
 P 0.553 0.678 0.580 1.000 1.000 0.890 1.000 0.330 
          
Cranial cruciate ligament 
IL-6 Kendal 0.18 0.02 0.04 0.12 -0.15 -0.19 0.01 0.33 
 P 0.302 0.888 0.800 0.446 0.324 0.225 0.933 0.064 
MCP-1 Kendal 0.19 -0.04 -0.15 -0.00 -0.03 0.07 -0.03 0.09 
 P 0.287 0.800 0.324 0.978 0.844 0.632 0.844 0.613 
TNF-α Kendal -0.15 0.02 0.02 -0.01 -0.02 -0.02 0.05 0.08 
 P 0.357 0.882 0.882 0.960 0.882 0.882 0.728 0.652 
AGC Kendal 0.04 -0.08 -0.16 -0.08 0.19 0.21 0.15 -0.25 
 P 0.797 0.575 0.262 0.575 0.191 0.135 0.283 0.128 
COL-1 Kendal 0.05 -0.09 -0.09 0.05 0.06 0.15 -0.04 -0.18 
 P 0.753 0.544 0.544 0.744 0.674 .283 0.779 0.289 
MMP-13 Kendal 0.06 -0.06 -0.04 -0.04 0.14 0.08 0.00 -0.21 
 P 0.716 0.692 0.771 0.812 0.355 0.616 0.979 0.223 
 
PVF: peak vertical force; VI: vertical impulse; FS: falling slope; AI: asymmetry index; IL-6: interleukin-6; TNF-α: tumour necrosis factor-α;  
MCP-1: macrophage chemotactic protein-1; AGC: aggrecan; COL-1: type 1 collagen; MMP-13: matrix metalloproteinase-13 (*P <0.05). 
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4.3.5 The relationship between body fat and chemical mediators in 
local and systemic adipose tissues 
In SC fat of dogs with CCLD, body fat mass (measured by DEXA) was positively 
correlated with adiponectin (P = 0.004) and leptin (P = 0.025) gene expression, but 
negatively correlated with MMP-13 (P = 0.001) gene expression. However, none of 
the mRNAs measured in the infrapatellar fat pad was associated with body fat mass 
(P > 0.05, Table 4.5).
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Table 4.5 Correlation between regional body fat and chemical mediators in adipose tissues. 
  Infrapatellar fat  Subcutaneous fat 
  Adiponectin Leptin Visfatin IL-6 MCP-1 TNF-α MMP-13  Adiponectin Leptin Visfatin IL-6 MCP-1 TNF-α MMP-13 
Body fat Kendal -0.22 -0.15 0.22 0.12 0.23 0.13 0.09  0.44** 0.36* -0.20 0.26 -0.36 -0.15 -0.55** 
P 0.173 0.410 0.103 0.372 0.082 0.361 0.509  0.004 0.025 0.215 0.123 0.100 0.418 0.001 
IL-6: interleukin-6; MCP-1: macrophage chemotactic protein-1; TNF-α: tumour necrosis factor-α; MMP-13: matrix metalloproteinase-13 (*P <0.05, **P < 0.01). 
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4.4 Discussion 
4.4.1 Differences in gene expression associated with CCLD 
4.4.1.1 Differences in gene expression of pro-inflammatory cytokines and 
tissue degradation biomarkers in disease and non-disease CCLs  
Several studies in humans have demonstrated that anterior cruciate ligament 
(ACL) injury induces increased inflammatory cytokine (IL-6, MCP-1 and TNF- α) 
expression, proteolysis of aggrecan, type I and type II collagen concentrations in 
synovial fluid, shortly after injury (Irie et al., 2003, Cuellar et al., 2010, Struglics et al., 
2015). Gene expression of cytokines and tissue degradation biomarkers such as IL-6, 
TGF-β1, collagen type 1 and MMPs have also been observed in different stages of 
human injured ACL tissues (Naraoka et al., 2012). However, few studies have 
investigated differences in gene expression between normal and diseased CCLs in any 
species (Clements et al., 2008, Leal et al., 2015). Results from this study 
demonstrated increased expression of IL-6, TNF-α and MCP-1 mRNA in injured CCLs 
when compared with controls. These results are consistent with previous studies 
which have demonstrated increased protein concentrations of IL-6 and TNF-α in 
synovial fluid from canine OA joints secondary to CCLD compared to controls (Hay et 
al., 1997, Fujita et al., 2006). 
Extracellular matrix (ECM) turnover is a normal physiological process in 
healthy tissue which is altered in the diseased state (Stetler-Stevenson, 1996); for 
example ECM turnover is more dynamic in injured ligament tissue, suggesting an 
attempt at tissue reparation (Lo et al., 1998, Comerford et al., 2004). The results of 
the current study are comparable to a previous canine study that demonstrated up-
regulation of mRNA expression for the genes involved in matrix remodelling, such as 
collagen type I and aggrecan, in injured ligaments compared to normal CCLs 
(Clements et al., 2008). Consistent with this study, the expression of MMP-13 is 
upregulated in human ruptured ACL (Muir et al., 2005), and also in canine and rabbit 
ruptured CCL tissues (Muir et al., 2005, Clements et al., 2006, Attia et al., 2010). 
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MMP-13 is one of the essential mediators playing roles in collagen destruction and 
degenerative joint diseases such as OA (Leeman et al., 2002, Wang et al., 2013). 
Taken together, expression of these biomarkers observed in the injured CCLs 
suggests changes in the inflammation, remodelling, and degradation processes 
occurring in these tissues. 
4.4.1.2 Differences in gene expression of pro-inflammatory cytokines and 
adipokines in disease and non-disease infrapatellar fat 
Human studies have identified IPFP as a local source of adipose tissue located 
within the joint capsule of the knee, close to the articular cartilage, synovium and 
bone (Saddik et al., 2004). Recently, IPFP has been suggested to be a source of local 
inflammatory cytokines and adipokines, which may contribute to the OA disease 
process (Distel et al., 2009, Iwata et al., 2013). There are several cytokines and 
adipokines which can be produced by IPFP in knee OA or patients with ligamentous 
injury for example IL-6, TNF-α, MCP-1, adiponectin, leptin and visfatin (Klein-
Wieringa et al., 2011, Clockaerts et al., 2012, Ushiyama et al., 2003). Expression of 
these cytokines, and also MMP-13 in IPFP as shown in this study, suggests that these 
chemical mediators are present in canine IPFP.  
There was an upregulation of IL-6 gene expression in IPFP derived from the 
dogs in our study with CCLD (Figure 4.1B). IL-6 is an important biomarker of 
inflammation (Heinrich et al., 1990) and increased expression of IL-6 in the IPFP has 
been associated with knee pain (Witonski et al., 2010). Moreover, previous work in 
OA patients has detected an increase in IL-6 secretion from IPFP as compared to SC 
adipose tissue (Klein-Wieringa et al., 2011). Therefore, the increased IL-6 gene 
expression found in the IPFP of dog stifle joints suggests that this adipose tissue might 
be inflamed in CCLD. However, down-regulation of adiponectin, leptin and MMP-13 
was seen in IPFP of the clinical group as compared to the controls. These findings 
contradict the results of previous studies, for example a study in human knee joints 
demonstrated increased leptin expression in IPFP obtained from OA patients as 
compared to healthy donors (Conde et al., 2014). Moreover, a microarray study 
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reported upregulation of both adiponectin and leptin transcripts at end-stage of 
human OA IPFP as compared to the early-stage OA IPFP (Gandhi et al., 2011). 
However, it is possible that IPFP is not the only source of adipokines in the stifles, 
since they can be synthesised by other joint tissues such as synovium, osteophytes 
and bone (Presle et al., 2006). Both pro- and anti-inflammatory mediators are also 
secreted by IPFP (Ioan-Facsinay and Kloppenburg, 2013); nonetheless, some previous 
studies have suggested a protective role of IPFP, by reducing catabolic process of 
cartilage for example in suppressing nitric oxide, glycosaminoglycan release and 
MMP expression in cartilage (Bastiaansen-Jenniskens et al., 2012). Therefore, the 
combined effect of these mediators is difficult to predict, and the exact stage of 
disease may affect the expression of adipokines in IPFP. However, we could not 
determine exact stage of the CCLD in the CCL samples included in this study. 
Additionally, it has been demonstrated that adiponectin stimulates the 
production of MMP-13 in synovial cells from RA patients to the same degree as IL-1β 
(Choi et al., 2009), whilst leptin in OA IPFP can enhance expression and production of 
MMP-1 and MMP-13 in human articular chondrocytes via mitogen-activated protein 
kinase pathways (Hui et al., 2012). In a similar manner, autocrine effects of 
adiponectin and leptin in IPFP might be responsible for the concurrence of gene 
expression of these adipokines and MMP-13 in the current study. 
4.4.1.3 Differences in gene expression of pro-inflammatory cytokines and 
adipokines in disease and non-disease subcutaneous fat 
In this work, there were divergent patterns between SC fat and the IPFP when 
comparing gene expression between cases and controls (except for IL-6 gene 
expression). Likewise, recent studies have demonstrated that the adipokine gene 
expression in IPFP correlates more closely with the severity of OA than adipokine 
gene expression in SC adipose tissue (Gandhi et al., 2015). Dissimilarities in gene 
expression of different proteins in mesenchymal stem cells derived from IPFP and SC 
fat have also been described previously (Lopa et al., 2014). The upregulation of both 
leptin and various inflammatory mediators (IL-6, MCP-1, TNF-α, MMP-13) in SC 
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tissues of dogs with CCLD that was seen in this study is also noteworthy. Although 
the reasons for these findings are not known, differences in body condition score 
might be responsible, not least because it was greater in clinical cases than in control 
dogs. Leptin is a well-known biomarker of obesity in many species (Hoenig et al., 
2007, Ishioka et al., 2007), whilst adipose tissue macrophages can secrete pro-
inflammatory cytokines, such as IL-6 and TNF-α, resulting in a low-grade 
inflammatory state (Ye et al., 2007). 
Some limitations of this study should be acknowledged. First, there were 
differences in the dog breeds represented in the two groups, with most of the control 
dogs being Staffordshire Bull Terriers, whilst a wider variety of dog breeds, in 
particularly Retrievers, were recruited for the clinical group. The differences between 
clinical cases and controls might be due to that the genetic differences amongst 
breeds (Mankowska et al., 2016). Moreover, most of the clinical dogs were neutered, 
whereas most dogs in the control group were entire. Not only obesity is more 
common in neutered dogs (McGreevy et al., 2005), but neuter status can also directly 
affect plasma adipokine concentrations in dogs (Damoiseaux et al., 2014). Therefore, 
it is important to be mindful that the results may be affected by these factors. 
4.4.2 The role of adipokines in canine CCLD 
Previous studies have suggested that adipokines may be predictive 
biomarkers of joint diseases such as OA and RA (Del Prete et al., 2014, Poonpet and 
Honsawek, 2014). In contrast, some studies have suggested that adiponectin may 
have beneficial effect on OA (Chen et al., 2006b, Gandhi et al., 2010), although 
evidence is conflicting. For example, plasma adiponectin concentrations in RA and OA 
patients are greater than in the controls (Otero et al., 2006, de Boer et al., 2012), 
whilst adiponectin concentration in synovial fluid from OA patients correlates with 
aggrecan degradation markers (Hao et al., 2011). Furthermore, adiponectin can 
induce nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes 
in vitro (Lago et al., 2008). In the current study, there was a positive correlation 
between IPFP adiponectin gene expression and pro-inflammatory cytokine (TNF-α) 
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concentrations in synovial fluid from the CCLD joints. Although low correlation 
coefficients and high p-values were noticed, it may be worth considering adiponectin 
as one of the potential mediators involved in degenerative joint diseases such as 
CCLD. 
In vitro studies have indicated that leptin and visfatin exert pro-inflammatory 
and pro-catabolic roles in OA (Otero et al., 2003, Gosset et al., 2008). The circulating 
serum leptin concentration is increased in humans with severe OA (de Boer et al., 
2012), whilst leptin concentration in synovial fluid is correlated with joint pain and 
severity of OA (Ku et al., 2009, Lubbeke et al., 2013). Increased expression of visfatin 
in the arthritic manus and pes extracts has been demonstrated in mice with collagen-
induced arthritis (Evans et al., 2011). Furthermore, visfatin inhibition effectively 
reduces the severity of disease, circulating TNF-α concentration and pro-
inflammatory cytokine secretion in affected joints of this murine model (Busso et al., 
2008, Evans et al., 2011). The work presented here has confirmed a positive 
relationship between synovial fluid leptin concentration and clinical lameness of dogs 
with CCLD, which were assessed both visually and by force plate measurement. It 
would have been helpful to have measured synovial fluid visfatin concentration. 
Unfortunately, it was only possible to collect a small volume of synovial fluid from 
each dog, and insufficient volumes were available for such measurements. 
Another observation of the current study was the variable correlation among 
some adipose-derived adipokines and cytokines in CCLs. For example, gene 
expression of IPFP visfatin was positively correlated with gene expression of CCL TNF-
α, whereas gene expression of SC visfatin were inversely correlated with gene 
expression of CCL TNF-α. Previous work has shown that osteophytes release more 
leptin and visfatin than synovium and IPFP (Presle et al., 2006, Chen et al., 2010). 
Therefore, adipokines derived from other articular tissues may contribute with mixed 
effects in the canine knee joint following CCLD. Further studies will be required to 
clarify this finding. These should include examination of the profile of adipokines in 
 101 
 
other joint tissues such as synovium and osteophytes, as well as synovial fluid visfatin 
concentrations. 
4.4.3 Pathway of local and systemic adipose tissues chemical mediators 
in CCLD 
Both local and systemic effects of obesity have been investigated in the 
development and progression of many diseases such as cancer, osteoarthritis and 
rheumatoid arthritis (Poonpet and Honsawek, 2014, Iyengar et al., 2015, Senolt, 
2017). Central adiposity is suggested to play a major role in the pathogenesis of OA 
(Wang et al., 2015). For example, plasma adiponectin and leptin concentrations are 
increased in OA subjects as compared to controls (de Boer et al., 2012), whilst some 
researchers have emphasised the destructive effects of local inflammatory mediators 
in OA disease (Clockaerts et al., 2010). In this study, there was an association between 
the amount of body fat and gene expression for some mediators such as adiponectin, 
leptin and MMP-13 in SC adipose tissue, but not in IPFP. This finding might suggest 
that there is a different regulatory pathway for adipokines in local environments 
compared with systemic adipose tissue. 
There were also differences in the patterns of adipokine expression in IPFP 
and SC tissues from dogs with CCLD and control dogs. These differences might result 
from varies in the baseline data of dogs recruited in the clinical and the control groups 
such as age, neuter status and body condition score. Previous studies have described 
possible effects of various baseline characteristics on adipokines pattern. For 
instance, plasma adiponectin concentration has been found to be lower in neutered 
dogs compared to intact dogs and negatively correlated with their age (Damoiseaux 
et al., 2014).  
Previous studies have also shown different patterns of adipokines presented 
in IPFP and SC adipose tissue in human knee OA (Distel et al., 2009), whilst recent 
work has suggested a closer association of metabolic activity in IPFP rather than SC 
in an early stage knee OA (Gandhi et al., 2015). In this study, some IPFP-derived 
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adipokines were associated with local mediators (for example adiponectin with 
synovial TNF-α, leptin with CCL MMP-13 and visfatin with CCL TNF-α). In contrast, 
only SC visfatin was correlated with synovial and CCL TNF-α. Therefore, these findings 
suggest an independent pathway between local and systemic chemical mediators in 
pathophysiology of the stifle joint.  
Finally, we unexpectedly observed a positive correlation with adiponectin 
gene expression in SC tissue and body adiposity, which contrasts with previous work 
suggesting increased fat mass to be inversely associated serum adiponectin 
concentration (Ricci and Bevilacqua, 2012). However, previous researchers have 
suggested that visceral adipose tissue, rather than SC adipose tissue, is involved in 
the secretion of systemic adipokines (Matsuzawa, 2006). Future work, sampling a 
source of visceral fat would be useful to improve our understanding of this.
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4.5 Conclusion 
This is the first study to examine the association between adipose tissue 
adipokines, inflammatory cytokines and ligament tissue degradation biomarkers in 
CCLD. Our data indicates the presence of inflammation in CCL, IPFP and SC tissues 
from dogs with CCLD. The contrasting pattern of adipokines expressed in IPFP and SC, 
as well as the lack of association between body fat mass and the IPFP adipokine 
profile suggest separate regulatory pathways of fat metabolism in the joint cavity. 
The various associations of IPFP-expressed adipokines with disease biomarkers in 
CCLs and joint fluid of dogs with CCLD such as IPFP adiponectin and SC visfatin with 
TNF-α in synovial fluid or may indicate that local adipokines are more likely to play 
roles in the disease. Moreover, it is interesting that leptin concentrations in synovial 
fluid appear to be an indicator for clinical lameness in dogs with CCLD.
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Chapter 5 Interaction of adipose tissues and adipokines 
with cranial cruciate ligaments 
5.1 Introduction 
The traditional understanding of adipose tissue as a large source of energy 
and body homeostasis regulator has been challenged since the discovery of leptin 
(Zhang et al., 1994). Adipose tissue, in particular white adipose tissue, is now 
identified as an active endocrine organ that synthesises and releases a variety of 
bioactive peptides. These proteins, termed adipokines, can act through endocrine, 
paracrine and autocrine mechanisms (Kershaw and Flier, 2004). In recent studies, 
adipokines have emerged as mediators of adverse health effects within the human 
musculoskeletal system (Lago et al., 2007a). Adiponectin, leptin and visfatin are well 
studied adipokines that are involved in inflammatory and immune responses within 
the body, and these processes become dysregulated in joint disorders such as in 
osteoarthritis (OA) and rheumatoid arthritis (RA) (Lago et al., 2007b, Toussirot et al., 
2007). 
Adiponectin is a powerful mediator that enhances the expression of 
connective tissue biomarkers such as metalloproteinase (MMP)-1 and -13 in synovial 
cells derived from RA patients (Choi et al., 2009). A recent study also demonstrated 
that adiponectin can increase nitric oxide, IL-6, MMP-1 and MMP-3 production in 
chondrocytes and OA cartilage in a mitogen-activated protein kinase-dependent 
manner (Koskinen et al., 2011). 
Various studies have shown that leptin is involved in bone development and 
cartilage metabolism (Gualillo, 2007, Upadhyay et al., 2015). However, leptin may 
provide a metabolic link between obesity and OA (Griffin et al., 2009). In severely 
osteoarthritic patients assessed by radiography, both the concentration of leptin in 
synovial fluid, and its gene expression in cartilage and joint osteophytes are greater 
than in tissues from healthy individuals (Dumond et al., 2003, Simopoulou et al., 
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2007, Ku et al., 2009). Moreover, leptin can induce the expression of biomarkers for 
cartilage damage such as MMP-9 and MMP-13 (Hui et al., 2012). Based upon this 
evidence, leptin is now identified as a key pro-inflammatory factor during joint 
disease (Toussirot et al., 2007). 
A more recent adipokine discovery, the adipokine visfatin has also been 
examined in musculoskeletal diseases. Clinical studies of human RA patients have 
demonstrated an association between the visfatin concentrations of both serum and 
synovial fluid and radiographic evidence of joint damage and inflammation (Brentano 
et al., 2007, Rho et al., 2009). Furthermore, a role in extracellular matrix-degradation 
has been suggested. For example, in vitro studies have demonstrated a catabolic 
effect of visfatin, when combined with IL-1, that stimulates the expression of 
metalloproteinase activity, nitric oxide production, and proteoglycan release in 
cartilage and meniscus explants (McNulty et al., 2011). Moreover, visfatin also 
significantly induces the expression of pro-inflammatory cytokines such as 
interleukin-6 (IL-6) and macrophage chemotactic protein-1 (MCP-1) in chondrocytes 
and osteoblasts (Laiguillon et al., 2014). 
Overall, significant evidence exists to support a key role for adipokines in the 
breakdown of articular tissues, and this may explain the link with biological effects of 
obesity in such joint diseases. However, so far no study has focused on the role of 
adipokines in cruciate ligament pathogenesis. Understanding the effect of adipokines 
on intra-articular tissue such as the cranial cruciate ligament (CCL) would be 
advantageous in defining whether they might represent therapeutic targets for 
ligament breakdown and therefore prevent joint disease. The assessment of 
biochemical markers of cartilage metabolism such as  collagen, extracellular matrix 
genes, proteases and their inhibitors have been used to detect the CCL injury (Harkey 
et al., 2015). The expression of matrix metalloproteinase (MMP)-13 gene and 
aggrecan (AGC) gene are believed to have a role in the pathogenesis of CCL, and 
would be changed in ruptured CCL when compared to normal CCL (Harkey et al., 
2015). 
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The hypothesis of this chapter was that both systemic and local (intra-
articular stifle joint tissues) cross-talk occurs between canine adipokines and articular 
tissue of dogs and these mechanisms can play a role in the pathophysiology of cranial 
cruciate ligament. 
5.1.1 Aims 
 To examine the cross-talk effect of both local and systemic adipose tissues on 
CCL explants in terms of glycosaminoglycan (sGAG) production. 
 To examine the effect of adiponectin, leptin, and visfatin on CCL cells in relation 
to cartilage degradation biomarkers gene expression, cell viability and migration 
activities.
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5.2 Methods 
5.2.1 Alteration of glycosaminoglycan content in CCL tissues 
5.2.1.1 Animals 
Eight control dogs and six dogs with CCLD (Appendix 3 Table 1-4) were used 
to obtain CCL, infrapatellar fat pad (IPFP) and subcutaneous (SC) fat explants in this 
study. Ethical permission for use of tissues and cadavers was approved by the local 
institutional ethical committees (Chapter 2 Section 2.1).  
5.2.1.2 Culture of explants 
Intermediately after tissue collection, CCL, IPFP and SC explants were cultured 
in complete media for 14 days in five different groups: 1) culture of CCL; 2) culture of 
IPFP; 3) culture of SC; 4) co-culture of CCL and IPFP; 5) co-culture of CCL and SC. Media 
were collected and changed every 3 days (Chapter 2 Section 2.4.1).  
5.2.1.3 Glycosaminoglycan assay 
To examine the possible role that adipose tissues and adipokines play in the 
pathogenesis of CCL tissue, we determined alterations of glycosaminoglycan (sGAG) 
in ligament explants after 14 days of co-culture with IPFP or with SC. Briefly, sGAG 
concentration in digested tissues and media of each cultured group were measured 
using 1,9-dimethylmethylene blue (DMMB)-based spectrophotometry method 
(Farndale et al., 1982) (Chapter 2 Section 2.4.6). 
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5.2.2 Investigating gene expression of cartilage degradation markers 
5.2.2.1 CCL cells culture 
CCL tissues from eight control dogs and six dogs with CCLD (Appendix 3 Table 
2) were isolated and cultured in T75 flasks (Chapter 2 Section 2.4.2). CCL cells at first 
or second passage were then transferred to culture in 24-well plates (Chapter 2 
Section 2.4.3). 
5.2.2.2 Cell treatment with adipokines 
CCL cells at 90% – 100% confluence in 24-well plates were treated in duplicate with 
recombinant human adiponectin, leptin and visfatin (PeproTech) at different 
concentrations (0.1 ng/mL, 1 ng/mL and 10 ng/mL), and at three different time points 
(1 hr, 6 hr and 24 hr) using 1 ng/ml dosage. 
5.2.2.3 Measuring gene expression of cartilage degradation markers  
Cells were harvested in 1ml of Tri-Reagent following exposure to adipokines at set 
time points. RNA extraction was performed from CCL cells after which cDNA were 
synthesised using reverse transcriptase. Then, qPCR was carried out to determine the 
gene expression for MMP-13 and aggrecan (AGC) in CCL cells and compared to 
negative controls (Chapter 2 Section 2.5.1.2-2.5.1.4). 
5.2.3 Investigating cell viability 
CCL cells isolated from six controls and six clinical dogs (Appendix 3 Table 3) 
were cultured in 96-well flat-bottom white tissue culture plates for 24 hours. The cells 
were then treated in triplicate with 10 ng/ml or 50 ng/ml of recombinant human 
adiponectin, leptin and visfatin for 48 hours. In addition, 200 μg/ml of 
lipopolysaccharide were used as positive controls. Then, cell viability was analysed 
using a CellTiter-Glo® Luminescent Cell Viability Assay kit according to the 
manufacturer’s protocol (Chapter 2 Section 2.4.4). 
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5.2.4 Measuring cell migration activity 
CCL cells isolated from one control and one clinical dogs (Appendix 3 Table 4) 
were cultured in collagen gel using a transwell system. The cells were treated with 10 
ng/ml of adipokines; adiponectin, leptin and visfatin, in the presence or absence of 
20 ng/ml recombinant human platelet-derived growth factor (PDGF-BB; R&D 
Systems), for 7 days. Cells treated with PDGF alone were used as positive controls. 
Histological sections of the collagen gels were processed and stained with 
haematoxylin and eosin. The percentage of migrating cells and maximum migrated 
distance were measured and compared to both negative and positive controls 
(Chapter 2 Section 2.4.5). 
5.2.5 Statistical analysis 
The statistical significance of differences between groups (section 5.2.1 – 
5.2.3) was determined using non-parametric Friedman test, followed by the Conover 
post-hoc test. In addition, 2-way non-parametric ANOVA was used to enable 
comparison between control and CCLD groups. Statistical software (StatsDirect 
version 3 for Windows, StatsDirect Ltd., Cheshire, UK) was used for the analysis, and 
data were considered statistically significant at P < 0.05.  
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5.3 Results 
5.3.1 Adipose tissues inhibit proteoglycan synthesis in CCLs 
We examined CCL explants from control dogs after 14 days of co-culture with 
IPFP or SC fat.  The sGAG concentration in CCL explants was decreased when co-
cultured with IPFP and SC fat, from 8.87 ± 4.20 µg/mg in controls to 5.66 ± 2.60 µg/mg 
and 6.39 ± 2.82 µg/mg in IPFP (P = 0.039) and SC fat (P = 0.020), respectively (Figure 
5. 1A) .  Whilst no significant change in sGAG content was observed between the 
different experimental groups when explants from dogs with CCLD were examined 
(Figure 5.1A). 
We also determined accumulated sGAG released in the media throughout 14 
days of the culture.  As with the explant experiments, the concentration of sGAG in 
the media of the co-culture groups, CCL with IPFP and CCL with SC fat, was decreased 
from 97. 62 ± 45. 43 µg/ ml to 29. 03 ± 28. 88 µg/ ml and 15. 62 ± 13. 10 µg/ ml 
respectively ( Figure 5. 2A) .  These differences were statistically significant for the 
media from the co-cultures of CCL and SC fat (P = 0.025, Figure 5.2B). No significant 
change in sGAG concentration was found in the media from the cultures of the CCLD 
group (Figure 5.2B). In addition, it was notable that the sGAG concentrations in media 
form CCLs collected from dogs with CCLD was less than control dogs; 28. 43 ± 19. 34 
µg/ml vs 97.62 ± 45.43 µg/ml (P = 0.006, Figures 5.1B).
  
1
1
1
 
A            B  
Figure 5.1 sGAG concentrations in different CCL culture groups. 
sGAG concentration in explants (A)  and media (B)  of different CCL culture groups from control dogs and dogs with CCLD.  Data are presented as 
mean and error bars represent the standard error (*P < 0.05 between culture groups, #P < 0.05 between control and CCLD groups). 
CCLD: cranial cruciate ligament disease; IPFP: infrapatellar fat pad; SC: subcutaneous fat; CCL+IPFP: CCL that was co-cultured with IPFP; CCL+SC: 
CCL that was co-cultured with SC fat. Figures show that the sGAG concentration in CCL explants of control dogs was significantly decreased when 
co-cultured with both IPFP and SC fat (A). sGAG concentration in the media of control dogs was also decreased when co-cultured CCLs with SC fat 
(B) .  The sGAG concentrations released in media form CCLs collected from dogs with CCLD is less than control dogs (B) .  However, there was no 
significant change in sGAG concentration when explants and media from dogs with CCLD were examined (A-B).  
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5.3.2 Alteration of cartilage degradation markers in response to 
adipokines stimulation 
Cells isolated from CCL tissue were cultured to form monolayers to determine 
marker gene responses to adipokine, which were adiponectin, leptin and visfatin, 
stimulation. A significant increase in MMP-13 gene expression was observed when 
CCL cells were stimulated with adiponectin at 0.1 ng/ml and 10 ng/ml in the CCLD 
group (P = 0.011 and P = 0.033 respectively, Figure 5.3B), but not in cells from the 
control group (Figure 5.2A). No significant differences in response to different 
concentrations of leptin and visfatin treatment were observed in either control or 
CCLD group (Figure 5.2B-C). There was no marked change in gene expression of AGC 
when CCLs were stimulated with different concentrations of adiponectin, leptin or 
visfatin in either control or CCLD groups (Figure 5.3A-C).
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Figure 5. 2 MMP- 13 gene expression in isolated CCL cells following treatment with 
different concentrations of adipokines. 
Changes in MMP- 13 gene expression of CCL cells derived from control and CCLD dogs in 
response to 0.1 ng/ml, 1 ng/ml and 10 ng/ml of adiponectin (A), leptin (B) and visfatin (C) 
for 24 hours. Data are presented as mean and error bars represent the standard error (*P 
< 0.05) .  CCLD:  cranial cruciate ligament disease, MMP-13:  matrix metalloproteinase-13. 
Figures show that MMP- 13 gene expression was significantly increased when CCL cells of 
CCLD group were treated with adiponectin at 0. 1 ng/ ml and 10 ng/ ml (A) .  There was no 
significant change in MMP-13 gene expression when CCL cells were treated with different 
concentrations of leptin and visfatin (B-C). 
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Figure 5. 3 AGC gene expressions in isolated CCL cells following treatment with 
different concentrations of adipokines. 
Changes in AGC gene expression of CCL cells derived from control and CCLD dogs in 
response to 0.1 ng/ml, 1 ng/ml and 10 ng/ml of adiponectin (A), leptin (B) and visfatin (C) 
for 24 hours.  Data are presented as mean and error bars represent the standard error. 
CCLD:  cranial cruciate ligament disease, AGC:  aggrecan.  Figures show that there was no 
significant change in AGC gene expression when CCL cells were treated with different 
concentrations of any adipokines (A-C). 
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We examined temporal response to adipokine exposure, and no significant 
change in MMP-13 gene expression was seen in cells from either the control or CCLD 
groups (Figure 5.4A-F). However, AGC gene expression in CCL cells from the control 
group was significantly decreased after 1 hr (P = 0.007), and then increased after 6 hr 
(P = 0.019) of 1 ng/ml visfatin stimulation (Figure 5.5E). However, there was no 
alteration in AGC gene expressions in response to visfatin in cells from the CCLD 
group (Figure 5.5F). 
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Figure 5. 4 MMP- 13 gene expressions in CCL cells following adipokines treatment at 
different time points. 
Changes in MMP-13 gene expressions of CCL cells derived from control (A, C, E) and CCLD (B, D, 
F) dogs in response to 1 ng/ml of adiponectin (A-B) leptin (C-D) and visfatin (E-F) at different time 
points.  Data are presented as mean and error bars represent the standard error.  CCLD:  cranial 
cruciate ligament disease, MMP- 13:  matrix metalloproteinase- 13.  Figures show no significant 
change in MMP- 13 gene expression when CCL cells from both control and CCLD group were 
treated with adipokines over a time course (A-F). 
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Figure 5. 5 AGC gene expressions in CCL cells following adipokines treatment at 
different time points. 
Changes in AGC gene expressions of CCL cells derived from control (A, C, E)  and CCLD (B, 
D, F)  dogs in response to 1 ng/ ml of adiponectin (A- B)  leptin (C- D)  and visfatin (E- F)  at 
different time points.  Data are presented as mean and error bars represent the standard 
error. CCLD: cranial cruciate ligament disease. Figures show no significant change in AGC 
gene expression when CCL cells from CCLD groups were treated with adiponectin, leptin 
and visfatin at various time points (B, D, F). In the control group, AGC gene expression was 
significantly decreased when CCL cells were treated with visfatin at 1 hr and increased at 
6 hr (E). 
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5.3.3 Adverse effect of adipokines on CCL cell viability 
In the control animals, CCL cell numbers were significantly decreased 
following treatment with 50 ng/ml adiponectin from 3,000 ± 1,420 cells (8,824 ± 
4,177 cells/cm2) to 2,501 ± 1,413 cells (7,357 ± 4,155 cells/cm2, P < 0.001, Figure 5.6). 
Following treatment with 10 and 50 ng/ml of leptin, the cell numbers decreased to 
2,687 ± 1,281 cells (7,903 ± 3,769 cells/cm2, P = 0.012) and 2,504 ± 1,373 cells (7,366 
± 4,039 cells/cm2, P < 0.001) respectively (Figure 5.6). Following treatment with 10 
and 50 ng/ml of visfatin, the cell numbers decreased to 2,675 ± 1,392 cells (7,869 ± 
4,093 cells/cm2, P = 0.001) and 2,292 ± 1,480 cells (6,742 ± 4,353 cells/cm2, P < 0.001) 
respectively (Figure 5.6).  
Similar results were observed in CCLs cells from dogs with CCLD. Reductions 
in CCL cell numbers were detected following treatment with 50 ng/ml of adiponectin, 
10 ng/ml and 50 ng/ml of leptin, 10 ng/ml and 50 ng/ml of visfatin, from 1,645 ± 1,508 
cells (4,839 ± 4,434 cells/cm2) to 1,446 ± 1,511 cells (4,252 ± 4,444 cells/cm2,                    
P < 0.001), 1,527 ± 1,500 cells (4,492 ± 4,412 cells/cm2, P = 0.019), 1,427 ± 1,472 cells 
(4,197 ± 4,330 cells/cm2, P < 0.001), 1,453 ± 1,429 cells (4,274 ± 4,202 cells/cm2,             
P = 0.002) and 1,374 ± 1,474 cells (4,040 ± 4,335 cells/cm2, P < 0.001) respectively 
(Figure 5.6).
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Figure 5.6 CCL cell number following adipokine treatment. 
These figures show the number of CCL cells isolated from control and CCLD animals after 
being exposed to 10 ng/ml or 50 ng/ml of adipokines; adiponectin, leptin and visfatin for 24 
hours.  LPS at 200 µg/ ml was used as a negative control.  Data are presented as mean and 
error bars represent the standard error ( *P < 0. 05, **P < 0. 01) .  CCLD:  cranial cruciate 
ligament disease; LPS: lipopolysaccharide. Figures show number of CCL cells were 
significantly decreased when cells from both control and CCLD group were treated with 
lipopolysaccharide and adipokines, except for adiponectin treatment at 10 ng/ml. 
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5.3.4 CCL cell migration activity in response to adipokines 
To examine how adipokines affected the migration of CCL cells. Therefore, the 
migration of CCL cells into collagen gels in the presence or absence of PDGF, a potent 
stimulator of migration (Figure 5.7A) following exposure to adipokines was 
examined. The result showed robust invasion of CCL cells into the collagen gel when 
PDGF was present (Figure 5.7B). 
 
 
  
A      B  
Figure 5.7 Migration activities of CCL fibroblasts. 
Cross-sectional images of CCL cells cultured atop three-dimensional collagen gels in either 
the absence (A) or presence (B) of PDGF (20 ng/ ml)  for 7 days.  The number and the 
distance of CCL cells invading (one- head arrows)  into collagen gel (depth indicated by 
double- headed arrows)  were examined.  Figures show no invasion of CCL cells in the 
absence of PDGF (A), but there was invasion of CCL cells in the presence of PDGF (B). 
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Given the small number of experiments (one per group), no statistical analysis 
was performed and therefore conclusions on the results of this experiment were 
inconclusive. However, data on cell migrating numbers of the control group showed 
that adiponectin and leptin treatment alone and when combined with PDGF caused 
a reduction in cell migration from 4.5% to 1.7% and 0% respectively (no PDGF), and 
from 34.3% to 12.9% and 17.8% respectively (with PDGF), Figure 5.8A. In contrast, 
visfatin treatment alone increased the number of migrating cells from 4.5% to 13.5% 
(Figure 5.8A). Visfatin combined with PDGF treatment slightly decreased cells 
migration number from 34.3% to 29.4% (Figure 5.8A).  
In the clinical group, none of the cells in the negative control and leptin 
treatment groups migrated through the collagen gel, whereas adiponectin and 
visfatin treated groups induced an increase in 2.6% and 11.1% of cell migration 
number, respectively (Figure 5.8B). In comparison, combinations of adiponectin and 
visfatin with PDGF reduced the percentage of CCL cells migrating from 14.8% to 3.2% 
and 5.9% respectively (Figure 5.8B). Unfortunately, we could not obtain data from 
leptin combined with PDGF treatment in the clinical cells due to a technical problem. 
In terms of the migration distance of CCL cells isolated from control animals, 
adiponectin treatment alone and with PDGF reduced the distance of cells migrating 
from 12.9 µm to 7.1 µm, and from 45.8 µm to 34.0 µm respectively (Figure 5.8C). 
Leptin combined with PDGF treatment also reduced the distance of cell migrating 
from 45.8 µm to 35.3 µm (Figure 5.8C). In contrast, visfatin treatment alone and with 
PDGF increased the distance of cell migration from 12.9 µm to 24.1 µm, and from 
45.8 µm to 65.5 µm respectively (Figure 5.8C). In addition, the maximum distances of 
cell migration in the clinical group were 36.8 µm and 38.8 µm in adiponectin and 
visfatin treatment respectively. With PDGF, adiponectin treatment increased the 
maximum distance from 28.7 to 48.0 µm. Conversely, visfatin combined with PDGF 
resulted in the shortest maximum distance at 9.2 µm (Figure 5.8D).  
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A         B  
C          D  
Figure 5.8 The change in CCL cells migration after adipokines exposure.  
The migration of CCL cells (%) of control (A) and CCLD group (B); as well as, maximum migrating distance in control (C) and CCLD group (D). CCLD: cranial 
cruciate ligament disease; PDGF:  platelet- derived growth factor.  In the control group, decreased cell migrating number and distance migrated was 
observed in adiponectin and leptin treatment groups, whilst increased cell migrating number and distance migrated in visfatin treatment group were seen 
visually (A, C). In the CCLD group, decreased cell migrating number but increased distance migrated were seen in adiponectin and visfatin treatment group 
(B, D). No result was seen for leptin treatment in CCLD group (B, D), and no statistical analysis was performed due to a small sample size (A-D). 
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5.4 Discussion 
5.4.1 Crosstalk effect of adipose tissues on CCL explants 
Obesity is one of the primary risk factors for OA in humans (Lago et al., 2007a) 
and CCLD in dogs (German et al., 2010b). Adipose tissue, the main energy store of 
the body, is also considered as a source of adipocyte-derived adipokines that can 
promote joint degeneration (Lago et al., 2007a). This chapter attempted to define 
the crosstalk between adipose tissues and cruciate ligament tissue using in vitro 
models.  
Proteoglycans are present on the cell surface, and within the ECM of most 
connective tissues, including ligaments (Esko et al., 2009). They have major roles in 
regulating collagen fibrillogenesis, encouraging tissue hydration and regulating cell 
to cell signalling, all of which help to maintain the structural integrity of ligaments 
(Iozzo, 1998). To investigate catabolic effect of adipose tissues on proteoglycans 
alteration in CCL tissues, concentration of sGAG in the tissues were examined using 
DMMB. It is noteworthy that the validation of the GAG assay in this study resulted in 
the negative slope of the DMMB standard curve at 570nm. A previous study has 
asserted that the ability of the DMMB assay to detect GAG depended on the 
phenomenon of metachromasia. For example, increasing GAG concentrations 
resulted in the decline of the 590 nm and 650 nm wavelength and a rise of 525 nm 
absorbance wavelength (Zheng and Levenston, 2015). 
In human studies, sGAG concentration comprised <1% of ACL tissue dry 
weight for both intact and ACL injury groups (Henninger et al., 2010, Young et al., 
2011). Some human and canine studies have shown a difference in the 
concentrations of sGAG present in normal and ruptured cruciate ligaments, but that 
was not observed in this study. A study in human ACLs has shown a greater sGAG 
content in the normal ACL than the injured ACL (Young et al., 2011). In contrast, a 
study in dogs has demonstrated that sGAG concentrations were increased in injured 
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CCLs (Comerford et al., 2004). In addition, sGAG content in normal fibrocartilaginous 
tissue is decreased with increasing age (Wang et al., 2006, Thornton et al., 2015). In 
the previous canine study, the mean age of the normal group was older than the 
normal group of this study (7.3 years vs 3.4 years) (Comerford et al., 2004). It may be 
possible that aging influences sGAG concentration in normal ligaments of dogs 
leading to the inconsistencies between the studies.  
The stage of disease is a factor that can affect the changes in ECM protein 
concentrations of injured joint tissues (Fu et al., 2007, Catterall et al., 2010). An 
inverse relationship between proteoglycan concentration in synovial fluid with stage 
of joint disease such as OA has been reported (Dahlberg et al., 1992). The findings 
from a human in vivo study have shown that acute ACL rupture (3 weeks onset) 
accelerated the secretion rate of sGAG from femoral weight-bearing cartilage into 
synovial fluid (Tiderius et al., 2005). It is possible that in our in vitro study created 
acute injury to the normal CCL tissues while the tissues have been cut. Therefore, we 
observed quite a high concentration of sGAG released in the culture media, 
compared to the ruptured group. Although we could not trace the exact onset of the 
CCL disease for every clinical dog in this study, the average disease stage was deemed 
to be approximately 6 weeks. 
In this study, co-culture of CCL explants with adipose tissue reduced the sGAG 
content of the CCLs, and also reduced sGAG loss from the explants (only in CCL+SC 
group) through the co-culture period. This phenomenon was only observed in the 
intact ligaments. Increased matrix turnover in the injured CCLs indicated by increased 
sGAG synthesis has been demonstrated previously (Comerford et al., 2004). 
Therefore, it is possible that the injured tissues might be able to compensate for 
sGAG turnover themselves. 
It has been shown that sGAG loss from tissue depends upon the quantity of 
sGAG remaining in the tissue matrix and the metabolic activity of the cells (Dahlberg 
et al., 1992, Tiderius et al., 2005). Our study suggests that there might be mediators 
in adipose tissues that can inhibit proteoglycan production in the ligaments, with 
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consequent decrease in sGAG release compared to control ligaments that were 
cultured on their own. Previous work has identified a degradative effect of adipokines 
on articular tissues. For example, treatment of porcine cartilage and meniscus 
explants with independent visfatin can enhance sGAG release (McNulty et al., 2011). 
Moreover, an in vitro study demonstrated that intraarticular injection of high-dose 
leptin into the rat knee depletes proteoglycan in articular cartilage (Bao et al., 2010). 
In addition, adipokines such as resistin, leptin, or visfatin reduce sGAG content in 
bovine meniscus explants, while inducing sGAG release into the conditioned media 
of the cultures (Nishimuta and Levenston, 2015). Therefore, it is possible that, similar 
to their influence on other articular tissues, adipokines and cytokines produced from 
adipose tissue may have important roles in catabolic degradation on CCL tissues by 
reducing sGAG content and inducing sGAG loss in the ligaments. These altered 
concentrations of proteoglycans are an important consideration as they will alter the 
biomechanical and functional properties of the ligament (Franchi et al., 2010).    
5.4.2 Effect of adipokines on cartilage degradation markers in CCL cells 
The evaluation of inflammatory cytokines and biochemical markers of 
cartilage metabolism have been widely examined in the ACL (Harkey et al., 2015). In 
this study, we observed the alteration in the gene expression of MMP-13 and 
aggrecan in CCL cells after treatment with adipokines (adiponectin, leptin and 
visfatin). Of the MMP family of extracellular proteinases, which are active in 
degrading extracellular matrix proteins, MMP-13 is a key interstitial collagenase in 
connective and cartilaginous tissues (Stura et al., 2013). Therefore, it is commonly 
monitored in various pathological conditions including ligament tears and 
tendinopathy (Arnoczky et al., 2007, Xie et al., 2013). Our results showed that 
adiponectin (0.1 and 10 ng/ml) stimulated MMP-13 expression in CCL cells derived 
from the clinical group. Previous studies support our finding that adiponectin might 
contribute to synovitis and joint destruction by strongly stimulating MMP-1 and 
MMP-13 expression in synoviocytes from RA patients (Choi et al., 2009).  
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Other studies have found that leptin used at higher dosages than in our study 
(20 - 500 ng/ml) can induce the expression of MMP-13 in articular chondrocytes from 
OA patients (Pallu et al., 2010, Hui et al., 2012). In addition, it has been shown that 
median leptin concentration in synovial fluid of patients with knee OA is 42.08 ng/ml 
(Calvet et al., 2016). Taken together, concentration of leptin may have needed to be 
considerably higher than the concentration used in our study to see an effect on 
MMP-13 expression. This may explain why no change was observed by using 0.1 – 10 
ng/ml dosages.  
Aggrecan is an important proteoglycan, found in articular cartilage and 
cruciate ligaments, which provides tissues with load-bearing properties (Kiani et al., 
2002, Valiyaveettil et al., 2005). Preliminary studies suggest that aggrecan can be 
used as a biomarker of knee injuries and OA (Ahlen et al., 2015). Aggrecan synthesis 
markers are increased in the synovial fluid, serum and urine of patients with acute 
ACL injury (Svoboda et al., 2013, Struglics et al., 2015). Moreover, in painful 
tendinopathy, it has been reported that aggrecan mRNA expression was increased 
compared with normal tendons (Corps et al., 2006). Our results indicated that 
aggrecan gene expression in CCL cells from control animals was reduced after a short 
period (at 1 hr) of treatment with 1 ng/ml of visfatin. This agrees with previous 
studies, which demonstrated that visfatin down-regulated aggrecan expression, and 
decreased high molecular weight proteoglycans synthesis in mouse articular 
chondrocytes (Gosset et al., 2008). Another recent study has also shown that visfatin 
stimulated the expression of MMPs (MMP-3, MMP-12 and MMP-13) and down-
regulated aggrecan (Yang et al., 2015). Therefore, our study supports the evidence 
that visfatin exerts its catabolic function by down-regulating aggrecan in CCL cells, 
which may contribute to ligament degradation. Future work to confirm the effect of 
adipokines could involve increasing the dosage of adipokine treatment, and 
observing other matrix degradation-related biomarkers such as IL-6, MCP-1, MMP-2 
and MMP-9 (Stannus et al., 2010, Boland et al., 2014, Xu et al., 2015). 
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5.4.3 Effect of adipokines on CCL cell viability 
It has been suggested that adipokines are important for cell survival in many 
tissues (Iwamoto et al., 2004, Nepal and Park, 2015). This study indicates a dose-
dependent, detrimental effect of adiponectin, leptin and visfatin on CCL cell viability 
in both normal and injured groups. Consistent with this, previous studies have 
demonstrated that adiponectin induces both apoptosis and proliferation of human 
liver cells (Nepal and Park, 2015). However, this adipokine may have a beneficial 
effect on cell proliferation in other cell types, such as human osteoblasts (Luo et al., 
2005), the mouse ATDC5 cell line (Challa et al., 2010) and human periodontal 
ligament cells (Nokhbehsaim et al., 2014a). Additionally, previous research has 
shown that leptin decreases normal and OA chondrocyte proliferation (Simopoulou 
et al., 2007, Wang et al., 2016). In contrast, some studies have implied cell 
proliferation promoting effect of leptin in other tissues, such as mouse pancreatic 
beta cells (Tanabe et al., 1997), human iliac crest osteoblasts (Gordeladze et al., 
2002), human dental stem cells (Um et al., 2011) and human liver cells (Nepal and 
Park, 2015). 
Like other adipokines, visfatin can have either a positive or negative role on 
cell viability, depending upon the circumstances. For example, visfatin enhances 
proliferation of cultured human osteoblasts (Xie et al., 2007), and stimulates breast 
cancer cell proliferation (Park et al., 2014). However, it can also increase rates of 
apoptosis in rat intestinal mucosa (Zhou et al., 2017). Overall, although adipokines 
have a variety of effects on cell survival in different cell types, this study supports an 
adverse effect of adiponectin, leptin and visfatin on canine CCL cell viability. Further 
investigation into the pathway of adipokines action on cell death may identify 
therapeutic targets in the treatment of CCLD. 
5.4.4 Effect of adipokines on CCL cell migration 
The migratory property of cells can be an indicator for healing ability following 
tissue damage (Valluru et al., 2011). A recent study has observed a prominent effect 
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of adipocyte-conditioned media in induction of human vascular smooth muscle cell 
migration (Lamers et al., 2011). There is evidence that adiponectin stimulates 
endothelial cell migration and differentiation, which results in stimulated blood 
vessel growth in vivo in mouse Matrigel® plug implantation and in rabbit corneal 
models of angiogenesis (Ouchi et al., 2004). In contrast, leptin decreases the number 
of migrating chondrogenic progenitor cells (Zhao et al., 2016), and negatively 
interferes with the regenerative capacity of periodontal healing in an in vitro wound 
healing model (Nokhbehsaim et al., 2014b). Furthermore, visfatin has a promoting 
effect in cell migration capability of human umbilical vein endothelial cells (Xiao et 
al., 2009). 
The data presented in this migration study were pilot results performed 
during a three-week period, while the researcher (WS) was attending a student 
exchange programme in Dr.Christopher Mendias’s laboratory at the University of 
Michigan, USA. Due to time constraints, only a limited number of experiments could 
be run. The subjective differences in migration patterns when stimulated with 
different adipokines might suggest that they influence CCL cell migration, and have a 
potential role in the healing ability following the CCL damage.  
Some limitation of these studies was that using adipokine’s vehicle for the 
controls, instead of no treatment, would give more precise results. Also, more 
samples and further work are required to better clarify if and how adipokines from 
adipose tissue impact CCL tissue.  
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5.5 Conclusion 
This is the first study to demonstrate an influence of adipose tissues and 
adipokines on cruciate ligament biology. The explant co-culture system 
demonstrated a reduction in the sGAG content in intact ligaments cultured with both 
local (IPFP) and systemic (SC fat) adipose tissues. Adiponectin and visfatin played 
roles in regulating MMP-13 and aggrecan gene in CCL cells respectively. In addition, 
adiponectin, leptin and visfatin had adverse effects on ligament cell viability. Overall, 
these results suggest an overall catabolic impact of adipokines on CCL tissues and 
cells, and provide an important first step in understanding the potential role of 
adipokines in regulating cruciate ligament metabolism. However, these adipokines 
may have different effects in the context of normal and pathological ligament tissues, 
and the findings must therefore be evaluated further. Understanding these 
mechanisms may point us toward therapeutic targets for disrupting the pathological 
mechanisms that lead to cruciate ligament disease. 
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Chapter 6 Final discussion 
6.1 General discussion 
Cranial cruciate ligament disease (CCLD) is one of the most common 
musculoskeletal diseases in dogs, and a major cause of stifle osteoarthritis (OA). The 
disease has important consequences both in terms of morbidity and cost associated 
with its management. Despite this, there are many gaps in understanding of its 
aetiology and pathogenesis which in turn means that preventive strategies and 
therapy are far from perfect. Obesity is known to be an important risk factor of CCLD 
(Adams et al., 2011). White adipose tissue has recently been recognised to be an 
active endocrine organ that synthesises and releases various adipokines and 
cytokines. In humans, these chemical mediators are thought to promote 
musculoskeletal impairment such as OA and rheumatoid arthritis (RA) (Lago et al., 
2007a). This is the first study to investigate the association between adipose tissue 
and canine CCLD, through both mechanical and humoral factor mechanisms. 
Specifically, dogs with CCLD were studied to examine the link between adiposity and 
clinical presentation. We further investigated roles of local and systemic adipokines 
in the CCL and other tissues of the stifle joint. In addition, we performed in vitro 
experiments to examine the direct effects of adipose tissue and adipokines on CCL 
tissues and cells. 
6.1.1 Impact of obesity on clinical presentation of dogs with CCLD 
One of the main questions examined in this study was to determine the 
influence of obesity-related factors on the clinical presentation of dogs with CCLD. 
One finding was that excess bodyweight was associated with the severity of 
lameness, perhaps suggesting a role for increased mechanical loading in 
pathogenesis of CCLD. This would have implications both for dogs of large breeds not 
least those predisposed to CCLD (Witsberger et al., 2008). Whilst this association 
might also have been the result of excessive body fat mass, the lack of association 
  
131 
 
with body fat mass (measured by DEXA) makes this unlikely. That said, the population 
studied was small and numbers may have been insufficient to separate a possible 
effect of body fat mass from the breed effect. This association between bodyweight 
and severity of lameness in dogs with CCLD agrees with findings from studies of the 
human knee, whereby the repetitive effect of mechanical loading may lead to 
weakness and degeneration of the cruciate ligament (Johnson and Johnson, 1993, 
Moore and Read, 1996c). Moreover, joint pain is associated with synovial fluid leptin 
concentrations in human with end-stage knee OA (Lubbeke et al., 2013) and it was 
observed in our study that the concentration of synovial fluid leptin was also 
positively associated with the degree of lameness in dogs with CCLD. Taken together, 
these results suggest a contribution from both mechanical and humoral factors in the 
clinical presentation in dogs with CCLD. Further studies should now be considered to 
investigate these observations further, and also to determine whether mechanical 
and humoral effects are inter-related. 
6.1.2 Effect of adipose tissue and adipokines on the biology of the 
cranial cruciate ligament 
The novel findings were observed in our in vitro studies, which suggest 
possible biological interactions between adipose tissue and the canine CCL in both 
health and disease. In this respect, our co-culture experiments identified that adipose 
tissue may have a catabolic effect on glycosaminoglycan content in CCL explants. In 
addition, the direct effects of recombinant adipokines (adiponectin, visfatin) on CCL 
cell gene expression for MMP-13 and aggrecan was examined. These results are 
agree with those of previous studies which have also suggested a degradative effect 
of adipokines on glycosaminoglycan content of articular cartilage in rats (Bao et al., 
2010), pigs (McNulty et al., 2011) and cattle (Nishimuta and Levenston, 2015). 
Relationships amongst adipokines and disease biomarkers were also 
identified within the canine stifle joint of dogs with CCLD. For example, an association 
was identified between the gene expression of both infrapatellar fat pad (IPFP) 
adiponectin and subcutaneous (SC) fat visfatin and concentration of TNF-α in synovial 
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fluid. There were also associations between IPFP leptin gene expression and CCL 
MMP-13 gene expression and between both IPFP and SC visfatin gene expression and 
CCL TNF-α gene expression, which suggest degradation and inflammation process. 
Other studies have shown that adiponectin can induce both gene and protein 
expression of chemokines and cytokines (e.g. IL-6 and MMP-3) in synovial fibroblasts 
of rheumatoid arthritis patients (Frommer et al., 2010). Plasma adiponectin and 
leptin concentrations were also increased in the knee joint of OA subjects as 
compared to healthy subjects (de Boer et al., 2012). Visfatin is an important regulator 
of inflammation, cartilage catabolism and bone erosion (Busso et al., 2008, Evans et 
al., 2011), whilst recent studies have suggested that adipokines may regulate cell 
proliferation and cell death in various cell types (Iwamoto et al., 2004, Nepal and 
Park, 2015). This study has also shown a potential for adipokines (adiponectin, leptin, 
visfatin) to have adverse effects on ligament cell viability in dose-dependent manner 
suggesting that adipokines might be an important factor for CCL cell survival. 
However, further studies would be required to confirm these findings, not least to 
determine the mechanism for any such effects. 
6.1.3 Tentative pathway of the role of adipokines in the canine stifle 
joint 
This study investigated whether the basal production of adipokines and 
cytokines by local and systemic adipose tissue correlated with body fat mass. 
Correlations were identified between body fat mass and adipokine profiles in 
systemic (SC fat), but not in local (IPFP) adipose tissue. Moreover, discrepant results 
were identified in the gene expression of adipokines and others disease biomarkers 
between local and systemic adipose tissues. For example, compared with control 
dogs, leptin and MMP-13 were down-regulated in IPFP but up-regulated in SC of dogs 
with CCLD. In addition, although it is suggested that central adiposity plays a role in 
the pathogenesis of OA, some studies suggest that intra-articular mediators have a 
greater influence (Clockaerts et al., 2012). Differences between the genes expression 
present in IPFP and SC adipose tissues, as well as a closer association between 
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metabolic activity in the IPFP and gene expression of disease biomarkers than in the 
SC fat of OA patients have also been shown previously (Lopa et al., 2014, Gandhi et 
al., 2015). This study observed the relationship between various IPFP-derived 
adipokine gene expression (e.g. adiponectin, leptin, visfatin) and CCLD biomarkers in 
both synovial fluid and CCLs. In contrast, only SC fat visfatin gene expression was 
correlated with synovial and CCL TNF-α. Taken together, these results suggest 
independent pathways of regulation for adipokines expressed by local and systemic 
adipose tissue depots, with local adipokines having more of an influence in the 
pathogenesis of CCLD. 
6.1.4 Limitations of the study 
Although many of the aims of the current study were fulfilled, there were 
some limitations which should be mentioned. First, the baseline data of dogs 
recruited in the clinical and the control groups were different, for example: breed, 
neuter status, age, bodyweight and body condition score. Previous studies have 
described possible effects of various baseline characteristics on adipokines and 
disease biomarker activity. For instance, higher pro-MMP-2 concentrations have 
been demonstrated in Labrador Retriever CCLs as compared to Greyhound CCLs 
(Comerford et al., 2005). Increased expression of MMP-3 has also been found in CCLs 
from older Hounds, when compared with young Beagles (Muir et al., 2005). A sex-
specific difference has also been observed with some adipokines; for example, higher 
leptin concentration in synovial fluid from women with knee OA as compare to men 
(Presle et al., 2006). Moreover, plasma adiponectin concentration has been found to 
be lower in neutered dogs compared to intact dogs and negatively correlated with 
their age (Damoiseaux et al., 2014). Therefore, overall differences in animal 
signalment might be an alternative explanation for differences in findings from cases 
and controls. In further studies, more dogs with tighter signalment could be recruited 
to enable the effects of confounding to be explored statistically.  
A second limitation is that the fact that the stage of disease, such as partial 
and complete rupture, might have varied amongst different cases and this might 
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again have influenced gene expression pattern in our samples. In a similar manner, 
alterations in gene and ECM protein concentrations in adipose tissue and injured 
tissue at different stages of OA have been reported in humans (Catterall et al., 2010, 
Gandhi et al., 2015). 
We also measured adipokine profiles in SC adipose tissue and this might not 
have been representative of all systemic adipose tissue depots, not least since given 
the suggestion that visceral adipose tissue might have a greater influence on systemic 
adipokine profiles (Matsuzawa, 2006). SC fat was chosen because it was easily 
accessible and we used a standardised site that had been used before (Ryan et al., 
2010). Therefore, in future studies, concurrent assessment of adipokine profiles in 
blood circulation, in visceral fat, as well as in other joint tissues should be considered. 
The use of cadavers to source control tissues meant that it was not possible 
to measure body composition by DEXA and, instead, only BCS was assessed.  In this 
respect, different results can be obtained when measuring body composition by 
DEXA in cadavers and live (Lefebvre et al., 1999, Pearce et al., 2009). In addition, using 
cadavers as a control group for live animals might create some differences in terms 
of gene expression in body tissue, since it has been shown that there are some 
changes in expression of oxidative stress regulating genes between human cadaveric 
and live donor kidney tissues (Kainz et al., 2004). 
There was relatively poor inter-observer agreement for radiographic score, 
which contrasts with previous work using the same scoring system (Innes et al., 
2004). This is likely to be due to differences in the experience of the two observers, 
as previously suggested (Verhoeven et al., 2007). Choosing different subjective 
scoring systems; for example, using either 30-factor (Hurley et al., 2007) or 21-factor 
(Au et al., 2010) scoring systems, which include measuring different points of joint 
tissues such as soft tissue thickening, intraarticular mineralisation and stifle joint 
effusion. Those more strict classification instructions may help to improve both 
reader consistency, and also inter-observer agreement (Linney et al., 2011). 
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Moreover, it has also been suggested that observers are required to implement the 
scoring system the same way each time (Lee et al., 2015). 
It need to be mentioned that a problem of statistical analysis in this study 
might occur with multiple comparison when correlations among more than two 
groups were assessed by Kendall’ tau test (Table 3.4, 4.3, 4.4). The Bonferroni method 
should be employed as a post-hoc procedure of correcting p values to avoid a type I 
error in this circumstance (Armstrong, 2014).  
Finally, there were limitations in the volume of synovial fluid samples, so we 
could not test visfatin concentration. In addition, low numbers in the cell migration 
experiment, which made it impossible to perform statistical analysis, also needs to 
be mentioned. Therefore, more samples should be collected in future studies.  
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6.2 Conclusion 
This thesis provides initial steps in exploring the role of adipose tissue in 
regulating canine cruciate ligament metabolism both in health and disease. The study 
has identified the potential for both mechanical and humoral factors of obesity in 
CCLD severity, together with the disease activity in the stifle joints, and suggests a 
possible role of adipose tissue and adipokines in the aetiopathogenesis of CCLD. 
Additional findings include the possibility of an independent regulatory pathway of 
fat metabolism in the joint cavity, given closer associations with the disease 
biomarkers in CCL when compared to systemic adipose tissue. In vitro studies have 
also indicated cross-talk and catabolic effects of adipose tissues and adipokines on 
the CCL tissue explants and cells. Understanding how CCLD is affected by obesity, 
adipose tissue and adipokine will be beneficial for the disease prevention, 
management and therapeutic interventions.
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6.3 Future work 
There are several opportunities of further study that could be considered to 
expand the work undertaken in this thesis. For example, the positive correlation 
between lameness and synovial fluid leptin concentration observed in this work 
suggests that leptin might be a biomarker for lameness in dogs or involved in the 
disease severity. Therefore, it might be worth to test the serum leptin to confirm this 
effect.  
There might also be opportunities for therapeutic intervention, perhaps to 
influence the effect of adipokine on CCL tissue biology, for example by interfering 
with the effect of adipokine action on tissue degradation biomarkers in CCL tissue 
and cell death.  
Finally, the results of this study could be a comparative model for exploring 
influence of adipose tissue on pathogenesis of cruciate ligament disease in humans.
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Appendix 1: Body condition score system for dogs 
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Small dogs body condition score (copyright Royal Canin)  
 
  
  
172 
 
Medium dogs body condition score (copyright Royal Canin) 
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Large dogs body condition score (copyright Royal Canin) 
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Giant dogs body condition score (copyright Royal Canin) 
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Appendix 2: Radiographic assessment of osteophytosis
 176 
 
  
Score 0 
 
  
Score 1 
  
177 
 
  
Score 2 
 
  
Score 3
 178 
 
Appendix 3: Animal profile used in Chapter 5
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Table 1 Animal profile used in Chapter 5 Section 5.2.1 
Category Control (n=6) Clinical (n=6) 
Median (Range) Median (Range) 
Breed (n) Siberian Husky (1) 
Staffordshire Bull Terrier (5) 
American Bulldog (1) 
Border Terrier (1) 
Cross Breed (1) 
Labrador Retriever (2) 
West Highland White Terrier (1) 
Gender (n) Entire female (2) 
Entire male (4) 
Entire female (2) 
Neutered female (2) 
Neutered male (2) 
Age (mt) 42.0 (24.0 – 60.0) 69.0 (36.0 – 97.0) 
BCS (0/9 - 9/9) 5 (2 – 5) 6 (6 - 7) 
Bodyweight (kg)  22.7 (15.0 – 37.0) 30.0 (9.8 – 43.5) 
n: number; mt: month; BCS: body condition score; kg: kilogram 
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Table 2 Animal profile used in Chapter 5 Section 5.2.2 
Category Control (n=8) Clinical (n=6) 
Median (Range) Median (Range) 
Breed (n) Cross Breed (1) 
Jack Russell Terrier (1) 
Rottweiler (1) 
Staffordshire Bull Terrier (5) 
Cross Breed (1) 
Golden Retriever (2) 
Labrador Retriever (1) 
Siberian Husky (2) 
Gender (n) Entire female (2) 
Entire male (5) 
Neutered male (1) 
Entire female (1) 
Neutered female (3) 
Neutered male (2) 
Age (mt) 30.0 (24.0 – 36.0) 63.0 (35.0 – 91.0) 
BCS (0/9 - 9/9) 4 (3 – 5) 6 (4 - 7) 
Bodyweight (kg)  17.0 (11.0 – 26.0) 33.3 (20.0 – 39.7) 
n: number; mt: month; BCS: body condition score; kg: kilogram 
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Table 3 Animal profile used in Chapter 5 Section 5.2.3 
Category Control (n=6) Clinical (n=6) 
Median (Range) Median (Range) 
Breed (n) Jack Russell Terrier (1) 
Staffordshire Bull Terrier (5) 
Cross Breed (1) 
Golden Retriever (2) 
Labrador Retriever (1) 
Siberian Husky (2) 
Gender (n) Entire male (6) Entire female (1) 
Neutered female (3) 
Neutered male (2) 
Age (mt) 30.0 (24.0 – 60.0) 63.0 (35.0 – 91.0) 
BCS (0/9 - 9/9) 5 (2 – 5) 6 (4 - 7) 
Bodyweight (kg)  17.2 (13.0 – 35.0) 33.3 (20.0 – 39.7) 
n: number; mt: month; BCS: body condition score; kg: kilogram 
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Table 4 Animal profile used in Chapter 5 Section 5.2.4 
Category Control (n=1) Clinical (n=1) 
Median (Range) Median (Range) 
Breed (n) Jack Russell Terrier (1) Siberian Husky (1) 
Gender (n) Entire male (1) Neutered male (1) 
Age (mt) 36.0 - 35.0 - 
BCS (0/9 - 9/9) 5 - 6 - 
Bodyweight (kg)  15.0 - 33.2 - 
n: number; mt: month; BCS: body condition score; kg: kilogram 
 
 
